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Abstract 
        
         The past two decades have seen an explosive increase of obesity rates 
worldwide, with more than one billion adults overweight and 300 million of them 
obese.  Obesity and its associated complications have become leading causes of 
morbidity and mortality in the United States and major contributing factors to the 
rising costs of national health care. 
         The pathophysiology of obesity and type 2 diabetes in rodents and humans 
is characterized by low-grade inflammation and chronic activation of immune 
pathways in adipose tissue and liver. The CD40 receptor and its ligand, CD40L, 
initiate immune cell signaling promoting inflammation, but conflicting data on 
CD40L-null mice confound its role in obesity-associated insulin resistance. A 
clear understanding of how CD40 and its ligand communicate to regulate and 
sustain the inflammatory environment of obesity is lacking. Here we demonstrate 
that CD40 receptor deficient mice on a high-fat diet display the expected 
decrease in hepatic cytokine levels, but paradoxically exhibit liver steatosis, 
insulin resistance and glucose intolerance compared with their age-matched wild-
type controls. Hyperinsulinemic-euglycemic clamp studies also demonstrated 
insulin resistance in glucose utilization by the CD40-null mice compared with 
wild-type mice. In contrast to liver, visceral adipose tissue in CD40 deficient 
animals harbors elevated cytokine levels and infiltration of inflammatory cells, 
particularly macrophages and CD8+ effector T cells. In addition, ex vivo explants 
viii 
 
 
of epididymal adipose tissue from CD40-null mice display elevated basal and 
isoproterenol-stimulated lipolysis, suggesting a potential increase of lipid efflux 
from visceral fat to the liver.  
           These findings reveal that 1) CD40-null mice represent an unusual model 
of hepatic steatosis with reduced hepatic inflammation, and 2) CD40 
unexpectedly functions in adipose tissue to attenuate the chronic inflammation 
associated with obesity, thereby protecting against hepatic steatosis. 
 
Keywords 
Adipose tissue inflammation, CD40, CD8+ T cell, hepatic steatosis, insulin 
resistance 
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1.1 Historical views on obesity 
1.1.1 Fat is selected as a major energy reservoir in evolution 
         Fats and oils are universally used as reserved forms of energy in living 
organisms. Small lipid droplets (LDs) containing triglycerides (also called neutral 
fats or triacylglycerols) can be found frequently in certain groups of prokaryotes 
(e.g., Mycobacteria, Rhodococcus, Streptomyces, and Nocardia) [1]. In most 
eukaryotic cells, triglycerides form oily droplets in the aqueous environment of 
the cytosol, serving as depots of metabolic fuel. In vertebrates, specialized cells 
called adipocytes, or fat cells, store large amounts of triglycerides in the form of 
LDs that occupy most of the cell volume [2] (Fig. 1.1A). Triglycerides are also 
stored as oils in the seeds of many types of plants, providing energy and 
biosynthetic materials during seed germination. Adipocytes and germinating 
seeds contain lipases, the crucial enzymes that catalyze the hydrolysis of stored 
triglycerides, releasing fatty acids for export to sites where they are required as 
fuel.  
 
        There are two significant advantages to using triglycerides as stored fuels, 
rather than polysaccharides such as glycogen or starch:  
 
        1). Since the carbon atoms of fatty acids are more reduced than those of 
sugars (Fig 1.1B), fatty acids possess a higher calorific value. The yield from the  
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      Figure 1.1  (A) Light micrograph of adipose tissue (200x) 
                           A: adipocyte; MФ: macrophages stained with F4/80 antibodies 
      (B) Molecular structure of fatty acids and glucose 
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complete oxidation of fatty acids is about 9 kcal g–1, in contrast with about 4 kcal 
g–1 for carbohydrates and proteins. 
 
 
        2). Since triglycerides are hydrophobic, therefore unhydrated, organisms 
that carry fat as fuel do not have to carry the extra weight of water of hydration 
that is associated with stored polysaccharides (2 g per gram of polysaccharide). 
Consequently, a gram of nearly anhydrous fat stores nearly 7 times as much 
energy as a gram of hydrated glycogen, which is most likely the reason why 
triglycerides rather than glycogen were selected in evolution as the major energy 
reservoir. Soluble carbohydrates such as glucose and glycogen do offer certain 
advantages as quick sources of metabolic energy. However, the human body 
can only store less than a day’s energy supply in the form of glycogen. In 
contrast, moderately obese people with 15 to 20 kg of triglycerides deposited in 
their adipocytes could meet their energy needs for months. 
 
        Virtually all animal species, from Caenorhabditis elegans to Homo sapiens, 
have found a way to store excess energy in the form of fat for future needs 
(Figure 1.2) [3]. C. elegans store fat in the intestinal epithelium [4] , while sharks 
store fat in the liver [5]. In most species, fat storage occurs in white adipose tissue 
(WAT). WAT locations vary among species. For invertebrates, amphibians, and 
many reptiles, the largest fat storage sites are intra-abdominal; in seals and 
whales, most fat is subcutaneous, whereas most of the mammals and birds have  
5 
 
 
 
 
 
 
Figure 1.2 Evolution of Adipose Tissue Depots  
Adipose tissue distribution and fat storage have evolved dramatically. In the worm C. 
elegans, fat is stored in the intestine, whereas Drosophila have a defined fat body. 
Sharks use their liver to store fat. Intra-abdominal white adipose tissue (WAT) becomes 
apparent in carp (Cyprinus carpio), amphibians and reptiles. Differentiation of 
subcutaneous and internal WAT occurs in higher species, such as birds and mammals, 
exemplified here by the chicken (Gallus gallus domesticus), mouse (Mus musculus), and 
human (Homo sapiens). 
Adapted from Cell. 2007 Oct 19;131(2):242-56. 
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both intra-abdominal and subcutaneous WAT. Stored triglycerides can serve not 
only as energy stores but also as insulation against low temperatures. For 
example, hibernating animals like bears, reserve huge fat under the skin before 
hibernation. This seasonal fat storage serves the dual purposes of insulation and 
energy storage. 
 
1.1.2 A long look at human obesity 
 
         In the natural world, starvation, infection, predation and harsh environments 
(e.g., cold) have long been the major killers of animals as well as humans [6]. Of 
all the above-mentioned adversities, starvation accounts for a major part of 
overall mortality. Nearly every continent in the world has experienced a period of 
famine throughout history. Some areas in sub-Saharan Africa continue to have 
extreme cases of famine today. 
         Evolutionarily, natural selection rewarded the “energy-thrifty” [7, 8] genotypes 
of those who could store the greatest amount of fat from the least amount of the 
then intermittently available foods. This ability to store surplus fat from the least 
possible amount of food intake may have made the difference between life and 
death, not only for the individual but also for the species. Those who could store 
fat efficiently had an evolutionary advantage in the harsh environment of early 
hunters, fishers, and gatherers [9]. However, today, in the presence of a 
continuous nutrition surplus, the once advantageous genetic trait sets a stage for 
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excess adiposity, which leads to overweight and obesity. What Arizona’s Pima 
Indians have experienced over the past century becomes a living proof of the 
“thrifty gene” theory. These athletic hunters and assiduous desert farmers, once 
adopted a typical western lifestyle, soon exhibited the highest prevalence of 
obesity and type 2 diabetes of any ethnic group [10, 11]. 
         The word Obesity comes from the Latin obesitas, which means “stout, fat, 
or plump.” It was widely perceived as a symbol of wealth, prosperity, and fertility 
at times in history, and still is as such in some parts of the world. Sculptural 
representations of the human body, such as Venus of Willendorf (20,000-35,000 
years ago) and figurines from Çatalhöyük in Turkey ( around 7500 BC)  (Fig 1.3A 
and B), depict obese females, which probably reflects of the time the aesthetic 
value and cultural significance attached to the obesity. Increased “flesh” was 
desirable is also reflected in ancient eastern arts, such as imperial paintings often 
seen in the Tang Dynasty of China (Figure 1.3 C). 
         Although, obesity in early history was rare among the general population, 
the health hazards associated with obesity were recognized by physicians from 
many diverse cultures. For example, Greek physician Hippocrates (460 BC-370 
BC) noted the adverse effects of excess adiposity by stating that  “corpulence is 
not only a disease itself, but the harbinger of others” and “sudden death is more 
common in those who are naturally fat than in the lean” [12]. 500 years after 
Hippocrates, the leading Roman physician Galen recounted one of the earliest 
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case studies of treatment for obesity: “I reduced a huge fat fellow to a moderate 
size in a short time, by making him run every morning until he fell into a profuse 
sweat; I then had him rubbed hard, and put into a warm bath…Some hours after, 
I permitted him to eat freely of food, which afforded but little nourishment; and 
lastly, set him to some work [12]”.      
        Obesity was also familiar to Abu Ali Ibn Sina (c. 980–1037) (Avicenna in 
Latinized version), one of the most prominent Arabic medical figures.  In his 
medical encyclopedia, written in the early 11th century, Avicenna described the 
sweet taste of diabetic urine, and also referred to obesity and its dangers to 
health.  In the eastern world, the Hindu physicians, Sushrut and Charak (500-400 
BC) are credited with early recognition of the sugary taste of diabetic urine, and 
observed that the disease often affected overweight people who ate excessively, 
especially sweet and fatty foods. Chinese and Japanese words for diabetes are 
based on the same ideographs (糖尿病) which mean "sugar urine disease". 
         Despite such accounts, it was only much later in the18th century that the 
modern history of obesity emerged. There have been numerous attempts to 
quantify excess weight in ways that are appropriate for clinical practice, research 
and epidemiology. The Belgian astronomer and statistician Adolphe Quetelet 
(1796-1874) was one of the pioneers in developing mathematical measures of 
obesity. Quetelet suggested that the ratio of the subject’s weight divided by 
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Figure 1.3 Cultural elaborations and aesthetic value of obesity  
(A) The Venus of Willendorf, Naturhistorisches Museum, Vienna, Austria 
          (B) Seated Woman of Çatal Hüyük, Ankara Museum, Turkey,  
(C) Du Qiu Figure by Zhou Lang, 1271-1368, the Palace Museum, Beijing, China.  
A. B. 
C. 
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the square of the height could be used as a measure of fatness that corrected for 
differences in height (see below). This unit, the Body Mass Index (BMI), has 
been shown to correlate with body fat content, and to predict risk for several of 
the comorbidities of obesity.                                                                                                                                   
 
                             
(  )
       (  )
 
 
 
1.2 Obesity has become a worldwide epidemic 
         Industrialized agriculture, hygiene and technology advances have made 
remarkable progress in alleviating our ancient challenges of starvation, infection 
and predation. However, novel threats are taking place, such as cardiovascular 
disease, type 2 diabetes, and cancer, which rapidly represent an increasing 
share of human morbidity and mortality. In recent years, obesity has emerged as 
the driving force behind these disturbing chronic diseases. According to the 
World Health Organization (WHO) reports in 2008, 44% of diabetes burden, 23% 
of ischemic heart disease burden and between 7% and 41% of certain cancer 
burdens are attributable to increased body weight and obesity. 
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The WHO definition of overweight and obesity is as illustrated in Fig 1.4: 
 BMI greater than or equal to 25 is overweight 
 BMI greater than or equal to 30 is obesity. 
         
        The Centers for Disease Control and Prevention (CDC) recorded the 
historical data of obesity prevalence in the United States from 1985 through 2011 
via its Behavioral Risk Factor Surveillance System (BRFSS) (Fig 1.5), which is a 
cross-sectional telephone survey conducted by state health departments. In 1990, 
among states participating in the BRFSS, no state had obesity prevalence equal 
to or greater than 15%.  In 2010, no state had a prevalence of obesity less than 
20%. Thirty-six states had a prevalence equal to or greater than 25%; 12 of these 
states (Alabama, Arkansas, Kentucky, Louisiana, Michigan, Mississippi , Missouri, 
Oklahoma, South Carolina, Tennessee, Texas, and West Virginia) had a 
prevalence equal to or greater than 30% [13-18]. The most recent data from 
National Health and Nutrition Examination Survey (NHANES) in 2009–2010 
reported that 35.7% of U.S. adults were obese (Figure 1.6), defined as a BMI ≥ 
30kg/m2.  
       Worldwide, from 1980 to 2008, the number of obese individuals doubled to 
more than half a billion people, eclipsing the number of underweight individuals 
for the first time in human history and driving the obesity-attributable death rate to 
~3 million per year [19]. Overall, more than 10% of the world’s adult population are 
now obese. Once considered a problem only in high-income countries,  
12 
 
 
 
 
 
 
 
 
Figure 1.4 Body Mass Index (BMI) classifications  
from World Health Organization 
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overweight and obesity are now dramatically on the rise in low and middle-
income countries. For example, China, the largest and most populous developing 
country in the world, used to have one of the leanest populations [20]; is now 
rapidly catching up with the West not only in the economic growth but also the 
prevalence of obesity. Roughly 25% of Chinese adults are currently overweight 
or obese. China is now home to the world’s largest diabetic population, with 92.4 
million adults having diabetes and 148.2 million adults that are prediabetic in the 
year of 2008 [21].  
         There is no doubt that energy imbalance between calories consumed and 
calories expended causes obesity, but the question is what is producing the 
positive energy balance that promotes the increasing prevalence of obesity? 
Many causes exist for the obesity epidemic. Heredity and prenatal or early life 
influences certainly contribute to obesity, however, the most important causes of 
overweight and obesity are probably related to the overconsumption of highly 
processed, energy-dense foods and the reduction of physical activities of the 
modern sedentary lifestyle. We have unintentionally created an environment that 
heavily favors metabolic overloads. Combatting the rise of obesity rates 
worldwide will require addressing both individual behavior and this “obesogenic” 
environment [22]. 
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Figure 1.5  Obesity Trends Among U.S. Adults 
BRFSS, 1990, 2000, 2010  
Adapted from  
the CDC website (http://www.cdc.gov/obesity/data/index.html) 
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Figure 1.6 Prevalence of obesity among adults aged 20 and over, by sex 
and age: United States, 2009–2010 
SOURCE: CDC/NCHS, NHANES. 
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1.3 Health risks of obesity 
 
         Overweight and obesity diminish almost every aspect of health. The rise in 
human obesity is closely associated with an alarmingly elevated incidence of 
diseases such as type 2 diabetes, fatty liver disease, cardiovascular disease, 
certain cancers, lung and musculoskeletal disorders, infertility, and other medical 
conditions including hyperglycemia, hyperinsulinemia, dyslipidemia and 
endothelial dysfunction [23] . Obesity causes these comorbidities by a variety of 
pathways, some as straightforward as the mechanical stress of carrying extra 
pounds and some involving complex changes in hormones and metabolism. 
Obesity decreases quality of life as well as life expectancy, and increases 
individual, national, and global healthcare burden. According to a recent study [24], 
the annual cost of managing obesity in the United States alone has climbed to 
approximately $190.2 billion per year, or 20.6% of national health expenditures. 
Obesity and its related disease clusters are now truly leading global public health 
problems. 
 
1.3.1 Obesity and insulin resistance 
         Insulin resistance commonly coexists with obesity and is a fundamental 
aspect of the etiology of type 2 diabetes. Insulin resistance is also linked to a 
wide array of other pathophysiologic consequences including hypertension, fatty 
17 
 
 
liver disease and atherosclerosis, which are often referred to as the “insulin 
resistance syndrome”, because resistance to insulin action in various 
tissue/organs/metabolic pathways is a common underlying feature of these 
complications [25]. 
        Of note, insulin resistance, although widely considered as a precondition to 
the onset of the metabolic syndrome, as one intrinsic cellular mechanism, is an 
evolutionarily conserved adaptive response in many physiologic contexts such as 
infection and pregnancy, which are unassociated with obesity.  Organisms have 
to maintain priority nutrient access for emerging metabolic requirements, such as 
fueling immune system activation or reserving metabolic resources for fetal 
development. Organisms meet these requirements by reducing systemic insulin 
sensitivity, decreasing nutrient uptake by non-priority cells and reserving glucose 
for priority cells and tissues [26, 27]. However, infection-  and pregnancy-associated 
insulin resistance is relatively transient and recedes to normal levels after the 
completion of these physiological processes, demonstrating that transient insulin 
signaling inhibition can be advantageous. In contrast, insulin resistance seen in 
obesity is fundamentally different from the above-mentioned physiological 
conditions because it is a chronic and pathological condition that occurrs before 
other metabolic complications. 
         During the progression from lean to overweight and obesity, adipose tissue 
expands to store excess energy in the form of triglycerides. Insulin promotes 
18 
 
 
adipocyte triglyceride storage by a number of mechanisms, including fostering 
the differentiation of preadipocytes to adipocytes, stimulating glucose transport 
and triglyceride synthesis, and inhibiting lipolysis. The insulin signaling cascade 
that initiates these events is largely conserved throughout evolution from C. 
elegans to Drosophila melanogaster and humans (Fig. 1.7) [28]  
        Insulin-mediated reducations in blood glucose levels result from increased 
glucose uptake by insulin-responsive peripheral tissues such as muscle, liver and 
adipose tissue as well as hepatic glucose production suppression. Skeletal 
muscle has long been considered to be the major site of insulin-stimulated 
glucose uptake in vivo, whereas adipose tissue was thought to only account for a 
small fraction of total body glucose disposal [29]. However, some studies provided 
evidences implying a more important role of WAT in mediating systemic glucose 
homeostasis than was previously thought. For example, fat tissue specific 
overexpression of GLUT4 enhances whole body insulin sensitivity [30], and the 
increase of glucose uptake selectively in fat with β3 adrenergic receptor agonists 
improves whole body insulin-stimulated glucose disposal [31]. 
          Far from being merely an inert energy storage depot, in recent two 
decades, adipose tissue has been recognized as a major endocrine organ with 
wide-reaching effects on other organs and tissues [32].  Adipose tissue modulates 
metabolism by releasing non-esterified fatty acids (NEFAs), peptide hormones, 
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Figure 1.7 Signal transduction in insulin action 
The insulin receptor tyrosine kinase undergoes autophosphorylation when bound to 
insulin on the outer surface of the plasma membrane, which transduces its signal to IRS 
proteins. The cytoplasmic signaling starts with tyrosine phosphorylation of IRS, which 
leads to a diverse series of signaling pathways including the activation of PI3K, MAP 
kinase and AKT. These pathways act in a coordinated fashion to regulate vesicle 
trafficking, protein synthesis, and gene expression. 
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and proinflammatory cytokines [33, 34]. In obesity, the production of many of these 
products is up-regulated, showing signs of dysfunction in the adipose tissue. 
          Among the secretory factors that are released by adipose tissue, NEFAs 
may be one of the most critical factors in modulating insulin sensitivity, which 
also explains the paradox that either absence (such as lipodystropic conditions 
[35]) or excess of adipose tissue causes insulin resistance; because in both 
circumstances, circulating serum NEFAs levels are elevated. The increased 
serum NEFAs may be because of defective adipose tissue in the case of 
lipodystrophy or expanded adipose mass in the case of chronic over-nutrition.  
The deficit in the capacity of adipose tissue to store excess energy results in lipid 
accumulation at undesired sites such as liver, skeletal muscle and heart, a 
phenomenon that has been described as ectopic fat deposition [36]. As a result, 
both professional metabolic and bystander tissues are exposed to supra-
physiologic levels of metabolic substrates. 
          NEFA circulating in the plasma binds to albumin. Insulin resistance 
develops within hours of an acute increase in plasma NEFA levels produced by 
lipid emulsion infusion in humans [37]. On the other hand, insulin-mediated 
glucose uptake and glucose tolerance improve with an acute decrease in NEFA 
levels after treatment with acipimox, a nicotinic acid analogue and a potent 
inhibitor of adipose tissue lipolysis [38]. It has been proposed that increased NEFA 
delivery or decreased mitochondrial fatty acid oxidation results in an increase in 
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the intracellular fatty acid metabolites such as diacylglycerol (DAG), fatty acyl-
coenzyme A (fatty acyl-CoA), and ceramides, which, in turn, activate a kinase 
cascade leading to the serine/threonine phosphorylation of insulin receptor 
substrate-1 (IRS-1) and insulin receptor substrate-2 (IRS-2), and a reduced 
ability of these molecules to activate PI(3)K [39]. Subsequently, events 
downstream of insulin-receptor signaling are diminished (Fig 1.7).  
         Simple obesity is typically associated with insulin resistance; however, 
individuals with similar BMI and adiposity could display remarkably various levels 
of insulin sensitivity [40]. Part of this differences is because of alterations in body 
fat distribution. Individuals with a more peripheral distribution of fat are more 
insulin sensitive than individuals who have their fat distributed centrally-that is, in 
the abdominal areas [41]. Hypertrophied intra-abdominal or visceral adipocytes 
are characterized by a hyperlipolytic state that is resistant to the antilipolytic 
effect of insulin [42, 43]. The resulting NEFA flux travels directly to the liver via the 
hepatic blood supply (portal circulation), which may impair liver metabolism and 
cause hepatic insulin resistance, apolipoprotein B-containing lipoprotein 
overproduction, and increased hepatic glucose production. In addition to altered 
NEFA metabolism, expanded visceral adipose also leads to an altered 
proinflammatory profile including elevated plasma C-reactive protein (CRP), IL-6, 
TNFα and reduced adiponectin concentrations [44].  
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1.3.2 Obesity and nonalcoholic fatty liver disease 
         Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease 
in both adults and children and is characterized by the pathological accumulation 
of hepatic lipids without significant alcohol consumption. NAFLD is strongly linked 
to obesity, insulin resistance and other metabolic complications and is a robust, 
independent marker of metabolic dysfunction [45, 46]. Obese persons who have 
normal liver lipid content tend to be resistant to developing obesity-related 
metabolic complications [47]. As a spectrum of diseases, NAFLD can progress 
from vesicular lipid accumulation in hepatocytes (simple steatosis) to 
steatohepatitis (NASH; steatosis with the presence of inflammatory infiltrate 
possibly with some fibrosis) to advanced fibrosis, cirrhosis, liver failure, and 
hepatocellular carcinoma (Fig 1.8) [48]. 
         Evidence from liver biopsies and imaging (ultrasound, computed 
tomography, MRI and proton magnetic resonance spectroscopy) studies [49] have 
demonstrated NAFLD in 20-35% of populations worldwide, with 10% of these 
cases being NASH. NAFLD prevalence is much higher among obese patients [50, 
51] and type 2 diabetic patients [52]. A disturbance in the balance between the 
processes of lipid accumulation and lipid disposal causes hepatic steatosis. The 
potential sources of fatty acids that contribute to fatty liver development include 
dietary fatty acids arising from intestinal chylomicron uptake, newly synthesized 
fatty acids within the liver and circulating NEFA.   
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           Hepatic lipids are disposed mainly through VLDL secretion or via 
mitochondrial β-oxidation. Defects in either of these pathways are associated 
with NAFLD. Stable isotope studies in rodents and humans have revealed that 
the excessive triglyceride accumulation as observed in hepatic steatosis occurs 
mainly because of increased hepatic lipogenesis and increased FFA influx from 
hypertrophied adipose tissue, whereas lipid disposal through β-oxidation or 
export has only minor effects [53].  
          NAFLD is often associated with adipose tissue and  hepatic insulin 
resistance [54]. Insulin resistance, in turn, affects both hepatic gluconeogenesis [55] 
and glycogenolysis [56]. Therefore, NAFLD patients have been documented to 
have increased gluconeogenesis [57, 58]. Excess fatty acids not only induce 
hepatic insulin resistance but also impair insulin clearance in vitro and in vivo [59, 
60], which contributes to the typical hyperinsulinemia of patients with NAFLD [61]. 
Hyperinsuliemia, in the context of elevated hepatic fatty acid flux as observed in 
obesity and NAFLD, stimulates hepatic sterol regulatory element binding protein 
1c (SREBP-1c) activity and is associated with increased hepatic de novo 
lipogenesis [62].  However, although de novo lipogenesis is up-regulated in 
NAFLD, it contributes less to the total hepatic triglyceride pool compared with 
adipose tissue-derived fatty acids. Donnelly et al. reported that in patients with 
NAFLD, 59% of the triglycerides labeled in the liver arose from circulating fatty 
acid flux (mainly from adipose tissue lipolysis), 26% from de novo lipogenesis 
and 15% from the diet [62]. 
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          Figure 1.8  Schematic representation of the pathophysiology of NASH 
               Adapted from Gastroenterology. 2012 Apr;142(4):711-72 
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        The most widely accepted model to describe NAFLD development and the 
progression from simple steatosis to NASH is the “two-hit hypothesis” [63]. The 
“first hit” is the aforementioned accumulation of lipids in the hepatocytes with 
insulin resistance as the key underlying pathogenic factor. The “second hit” leads 
to hepatocyte injury, inflammation and fibrosis. Factors initiating the second hit 
are oxidative stress and subsequent lipid peroxidation, mitochondrial dysfunction, 
and DNA damage. In addition, products of lipid peroxidation increase the 
expression of proinflammatory cytokines and recruit inflammatory cells into the 
liver. Inflammation plus hepatic stellate cells activation leads to collagen 
production and the initiation of fibrosis [64]. 
 
1.3.3 Obesity and Cardiovascular Disease 
        Body weight is directly associated with various cardiovascular (CV) risk 
factors, especially in individuals with a central deposition of adipose tissue [65].  
As BMI increases, so do blood pressure, low-density lipoprotein (LDL), 
cholesterol, triglyceride, blood sugar, coagulation, fibrinolysis and inflammation. 
All of these changes translate into increased risk for coronary heart disease 
(CHD), stroke, and CV death. There are numerous adverse effects of obesity in 
general and CV health in particular (Table 1.1) [66]. 
         It is well known that cigarette smoking is a classical CV risk factor. Smoking 
affects cytokines by causing a dose-dependent increase in plasma intercellular 
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adhesion molecule-1 (ICAM-1) and decrease in adiponectin levels [67], thereby 
inducing endothelial dysfunction. Smoking increases levels of TNF-α, a powerful 
cytokine that decreases adiponectin levels and induces insulin resistance. 
Smoking also enhances oxidative stress owing to the direct effects of the free 
radicals that are present in smoke. As described earlier, obesity exhibits almost 
the entire spectrum of adverse effects associated with smoking, including 
elevated inflammatory cytokines, attenuated adiponectin levels and increased 
oxidative stress. In fact, when compared with non-obese smokers, obese 
smokers have a clear reduction of life expectancy [68].  
        Numerous studies have demonstrated a direct link between excess body 
weight and CHD. Investigators conducted a meta-analysis of 21 long-term 
studies that followed more than 300,000 participants for an average of 16 years. 
Study participants who were overweight had a 32% higher risk of developing 
CHD, compared with participants who were at a normal weight; those who were 
obese had an 81% higher risk [69]. 
        Increased NEFA levels in obesity affect endothelial nitric oxide production, 
thereby impairing endothelium-dependent vasodilation. On the other hand, the 
dyslipidemia seen in obesity is characterized by an altered LDL particle 
composition and distribution, resulting in an increased concentration of small, 
dense LDL. LDL particles are enriched in triglycerides, which are rapidly lipolyzed 
by hepatic lipase (HL), leaving smaller, denser LDL particles.  These particles are 
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Table 1.1 Adverse Effects of Obesity 
A. Increases in insulin resistance  
1) Glucose intolerance  
2) Metabolic syndrome  
3) Type 2 diabetes mellitus 
B. Hypertension 
C. Dyslipidemia  
1) Elevated total cholesterol  
2) Elevated triglycerides  
3) Elevated apolipoprotein-B  
4) Elevated small dense LDL particles  
5) Decreased HDL cholesterol  
6) Decreased apolipoprotein-A1 
D. Abnormal left ventricular geometry 
1) Concentric remodeling  
2) Left ventricular hypertrophy 
E. Endothelial dysfunction 
F. Increased systemic inflammation      
    and prothrombotic state 
G. Systolic and diastolic  
     dysfunction 
H. Heart failure 
I. Coronary heart disease J. Atrial fibrillation 
K. Obstructive sleep apnea/sleep- 
    disordered breathing 
L. Albuminuria 
M. Osteoarthritis N. Cancers 
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more prone to oxidation/glycation and are mostly taken up by macrophage 
scavenger receptors instead of the LDL receptor pathway, which induces 
atherosclerosis. 
 
1.4 Inflammation as a link between obesity and metabolic syndrome 
          Metabolic syndrome, also known as syndrome X or insulin resistance 
syndrome is a combination of medical disorders that, when occurring together, 
increase the risk of developing cardiovascular disease, stroke, and type 2 
diabetes.  Reaven, in his 1988 Banting lecture, described “Syndrome X” as the 
association of insulin resistance, hyperglycemia, hyperinsulinemia, hypertension, 
low HDL cholesterol and elevated VLDL triglycerides [70]. However, he did not 
include obesity as a contributing factor leading to syndrome X. Today, obesity, 
especially abdominal obesity, is considered t be one of the most important 
criteria for the metabolic syndrome. 
          In the past two decades, the search for a potential unifying mechanism 
behind the pathogenesis of obesity-associated metabolic syndrome has revealed 
a close relationship between nutrient excess and an alternative form of 
inflammation, called “metabolic inflammation” [71], which is characterized by the 
chronic, low-grade inflammation that is observed in obesity.  
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          Appreciation of the involvement of inflammation in insulin resistance or 
type 2 diabetes started with the use of salicylate. In 1876, Ebstein first 
demonstrated that high doses of sodium salicylate could diminish glycosuria in 
diabetic patients [72]. In 1901, Williamson again pointed out that “sodium 
salicylate had a definite influence in greatly diminishing the sugar excretion” [73]. 
Of course, the hypoglycemic actions of salicylates and the molecular target of 
salicylates, IκB kinase-β (IKKβ)/NF-κB axis, were not known at the time [74, 75]. 
         The association between insulin resistance and inflammation was later 
recognized with the identification of insulin resistance in patients with sepsis [76]. 
We are now familiar of that many diseases with active inflammatory responses 
display insulin resistance as a feature, including hepatitis C, HIV, and arthritis [77-
79]. Direct proof of the link between inflammation and metabolic responses came 
from the genetic studies in mice by Hotamisligil and colleagues. They found that 
obese adipose tissue secretes inflammatory cytokines (such as TNFα) and these 
cytokines themselves can inhibit insulin signaling [80, 81].  
        As described earlier in this chapter, the ability to withstand starvation and 
the ability to fight off infections are critical functions for species survival. It is now 
appreciated that immune response and metabolic regulation are highly 
intertwined and evolutionarily conserved processes, therefore, proper function of 
one is dependent on the other. One example that represents this active 
interaction is the Drosophila fat body, which incorporates the mammalian 
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homologs of the liver, adipose tissue, and the hematopoietic immune system into 
one functional unit [82, 83]. The fly’s fat body carries out a crucial function in 
sensing energy availability. The fat body is also the site of coordination of 
pathogen responses with metabolic status [82]. It is very possible that, in the fly, 
common and overlapping molecular pathways regulate both metabolic and 
immune functions and in higher organisms, tissues or organs that are 
responsible for metabolism and immunity maintain their developmental heritage.  
As such, it is conceivable that nutrient surplus might be able to activate a 
pathogen-sensing system, such as the Toll-like receptors (TLRs) and NOD 
(nucleotide-binding oligomerization-domain protein)-like receptors (NLRs) [84] and 
metabolically induce inflammatory responses.  
 
1.4.1 Classic inflammation vs. Inflammation in obesity 
         Inflammation is usually referred to as classic acute inflammation, an 
adaptive response to harmful stimuli, such as infection, tissue injury and irritants.  
Acute inflammation is a protective attempt by the organism to remove the 
injurious stimuli, followed by a resolution and repair phase to restore 
homeostasis. The classic response of acute inflammation is a short-term and 
high-amplitude process, usually appearing within a few minutes or hours and 
resolving upon the removal of the injurious stimulus. Acute inflammation is 
characterized by five cardinal signs: pain, heat, redness, swelling and loss of 
function [85].  
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        In contrast, inflammation induced by metabolic surplus is distinctive and is 
not caused by the classic instigators of inflammation: infection or injury. Instead, 
this altered form of inflammation is associated with the malfunction of tissues that 
are not directly related to host defense or tissue repair. 
          First, the trigger of inflammation in obesity is different. In obesity-related 
metabolic syndrome, metabolic signals emerging from metabolic cells (such as 
adipocytes) induce inflammatory responses and deteriorate metabolic 
homeostasis. An array of inflammatory cytokines are increased in obese adipose 
tissue (and in adipocytes themselves), including TNFα, IL-6, IL-1β, CCL2, MCP-1, 
SAA and many others [34]. In addition to adipose tissue, the liver [86], pancreas [87], 
brain [88] and muscle [89] all possibly contribute to the elevated systemic 
inflammation in the obese state. Importantly, the obesity-associated inflammation 
discussed here, though significant, is often modest when compared with that of 
an infection or trauma. 
       Second, the duration of inflammation that occurs in obesity is vastly different 
from the duration of acute inflammation. Contrary to classic acute inflammation, 
in obesity, the increased inflammatory cytokine expression that occurs in various 
metabolic tissues and organs appears to happen gradually and remains 
unresolved over time. Several studies carefully examined the timing of obesity-
induced inflammation in mice and one reported that increases in inflammatory 
and macrophage-specific gene expression in adipose tissue occurred after 3-
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week of high-fat diet (HFD) feeding, with a more dramatic increase at 16 and 26 
weeks on the same diet [90].  Thus, it seems that the inflammation induced by 
nutritional overload is not dramatic enough as acute inflammation to mount a full 
resolution program, and therefore the low-grade inflammation is maintained in a 
chronic manner for years. This lack of resolution may be due to the lack of 
evolutionary selection to develop such a response to chronic energy surplus. 
 
1.4.2 Molecular pathways that link inflammation and insulin resistance 
        Obesity-associated tissue inflammation is now recognized as a major cause 
of decreased insulin sensitivity. How inflammatory signals disrupt insulin action in 
obesity has been an intensive area of research.  
        As demonstrated in Figure 1.7 and Figure 1.9, insulin receptors acquire 
docking proteins, insulin receptor substrates (IRS), to propagate downstream 
signaling cascades [91]. The tyrosine phosphorylation of IRS is a crucial step in 
insulin signaling and is inhibited by counter-regulatory serine/threonine 
phosphorylation [92]. IRS tyrosine phosphorylation is often defective in many 
cases of insulin resistance [33]. IRS-1 can be phosphorylated at inhibitory serine 
residues by a variety of kinases, such as JNK, IKKβ, S6 Kinase, mTOR and 
protein kinase C (PKC) and this serine phosphorylation on IRS-1 blunts insulin 
signaling [93-95]. In response to various metabolic stresses that occur in obesity, 
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JNK [93], IKK [96] and PKC [97] are often activated, which inhibits insulin action (Fig 
1.9).   
       More specifically, JNK activity increases dramatically in critical metabolic 
sites of obesity [98], such as adipose tissue, liver, and hypothalamus [99]. Upon 
exposure to cytokines, free fatty acids, reactive oxygen species, or endoplasmic 
reticulum (ER) stress, JNK is acutely activated [93, 100], which contributes to 
obesity-induced insulin resistance. These observations were validated by the 
JNK-1 genetic deletion in mice. JNK-1 deficiency protected mice from IRS-1 
serine phosphorylation, and improved systemic glucose homeostasis and insulin 
sensitivity [101].  
       IKKβ is another inflammatory kinase that is critical in the development of 
insulin resistance. As mentioned earlier, high dose salicylates administration 
improves insulin action by inhibiting IKKβ kinase activity [75]. Experimental 
activation of IKKβ in the liver is sufficient to cause systemic insulin resistance [86]. 
         Protein kinase C has various isoforms and is important for the interaction 
between inflammatory and metabolic pathways. PKC is thought to be 
downstream of lipid signals [102, 103]. Intermediate metabolites of fatty acids, such 
as fatty acyl-CoA, DAG, and ceramides may activate PKC-θ in muscle and PKC-
δ in the liver, which eventually inhibits insulin action [104]. PKC-θ knockout mice 
are protected from obesity-induced insulin resistance, confirming the contribution 
of this kinase to metabolic regulation in vivo [103]. 
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         In addition to IRS-1 serine phosphorylation, the inflammatory kinases 
mentioned above exert their effects through regulation of gene expression, 
including inducing inflammatory gene expression via activation of transcription 
factors, such as activator protein-1 (AP-1) and NF-κB [105].  When NF-κB 
pathways are activated, more inflammatory cytokines and chemokines, such as 
TNFα, IL-6, IL-1β and MCP-1 are produced, which further activates JNK, IKKβ, 
and PKC and establishes a stable, feed-forward signaling loop. Other 
mechanisms that link inflammation with insulin resistance may include 
suppressor of cytokine signaling (SOCS) proteins, which are involved in the 
degradation of IRS-1 [106], as well as organelle dysfunction [107]. 
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Figure 1.9 Insulin-receptor signaling interfaces with inflammatory signaling 
at the level of insulin-receptor substrates via activation of serine kinases 
Serine kinases (ERK, extracellular regulated mitogen-activated protein kinase; GSK3, 
glycogen synthase kinase 3; S6K1, ribosomal protein S6 kinase polymerase 1; TOR, 
target of rapamycin) respond to both lipids and cytokines. IRS contains a number of 
serine residues (indicated by stars) that are targeted by various kinases. 
Adapted from Nature. 2006 Dec 14;444(7121):860-7. 
 
 
 
36 
 
 
1.4.3 Resident and infiltrated immune cells in adipose tissue 
        Among one of the first organs that influenced by nutritional excess is the 
adipose tissue, which can communicate with other peripheral tissues through the 
release of adipokines, cytokines and fatty acids; thereby having effects on 
systemic inflammation and insulin sensitivity. Genetic manipulations within 
adipocytes that enhance local insulin sensitivity often improve systemic insulin 
sensitivity and glucose homeostasis  [108-111], indicating a primary role of adipose 
tissue in whole body metabolism. 
        One hallmark of the inflammatory state of obesity is increased immune cell 
infiltration into metabolic tissues, especially, WAT. Several types of stresses such 
as endoplasmic reticulum (ER) stress, oxidative stress and hypoxia are 
associated with adipose tissue expansion [107]. All of these cellular stresses result 
in the production of chemokines and proinflammatory cytokines, such as MCP-1, 
IL-6 and TNFα. The proinflammatory environment of obese adipose tissue 
activates not only resident leukocytes but also creates a chemotactic gradient 
that further attracts various inflammatory cells [112-115].  
 
1.4.3.1 Macrophages 
          Macrophages, the sentinels of innate immunity, reside in almost every 
tissue in the body, where they participate in various homeostatic functions in 
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addition to host defense. An important discovery that helped to elucidate the 
cause of tissue inflammation was that adipose tissues from obese animals and 
humans are infiltrated by large numbers of macrophages [115]. These cells display 
remarkable heterogeneity in their cell surface markers. By flow cytometry, 
macrophages are defined as F4/80+/CD11b+ cells. In the progression of weight 
gain from lean to obese, macrophage content increase from approximately 10% 
of all adipose tissue cells to over 50%.  
         Adipose tissue macrophages (ATMs) in lean and obese animals have 
different inflammatory potential along with distinct surface markers and cytokine 
signatures. In lean adipose tissue, macrophages are mostly alternatively 
activated M2-polarized macrophages, which are characterized by the presence 
of CD206 (mannose receptor) and macrophage galactose-type C-type lectin 1 
(MGL1), and can be further subdivided into M2a, M2b and M2c cells [116, 117]. M2 
macrophages in lean adipose tissue produce anti-inflammatory cytokines, such 
as IL-10 and IL-1 receptor antagonist (IL-1Ra) [118, 119]. However, obesity swaps 
macrophage population from an immunoregulatory M2 phenotype towards a 
proinflammatory M1 bias. In obese adipose tissue, M1-polarized macrophages 
known as classically activated macrophages express CD11c (integrin alpha X 
chain protein),  with diminished CD206 and MGL1 expression. M1 cells also 
express high levels of iNOS and proinflammatory cytokines (TNFα, IL-1β and IL-
6). These cytokines can act locally in a paracrine manner, or they can leak out of 
the adipose tissue and have systemic effects, thus decreasing whole body insulin 
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sensitivity [120-122]. Selective depletion of CD11c+ immune cells by utilizing 
conditional cell ablation system (based on transgenic expression of the diphtheria 
toxin receptor under the control of the CD11c promoter) resulted in reduced 
macrophage numbers as well as adipose tissue inflammation and improved 
insulin sensitivity in the diet-induced obese mice [123].  It is important to note that 
tissue macrophages respond to perturbations of energy homeostasis rapidly by 
constantly altering their transcriptional programs, thus, ATMs may actually 
represent a phenotypic spectrum. The M1/M2 classification described here is 
very likely an oversimplified view of more dynamic macrophage populations that 
are present in the adipose tissue.  
         In general, most adipose macrophages are thought to originate from bone 
marrow-derived monocytes, which infiltrate adipose tissue from circulation. 
However, recent data from our laboratory has shown that macrophages can 
undergo significant cell division within visceral and subcutaneous adipose tissues 
of obese mice, suggesting that in situ proliferation might also be an important 
mechanism by which ATMs accumulate (Amano et al. unpublished data). 
 
1.4.3.2 Lymphocytes 
        Other than macrophages, recent studies have revealed a growing list of 
immune cells that infiltrate obese adipose tissue.  
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        T cells, as one subset of lymphocytes have been shown to infiltrate adipose 
tissue during obesity. In 2009, three independent studies demonstrated the 
critical role of T cells in obese adipose tissue for the regulation of insulin 
sensitivity in genetic or diet-induced obese mouse models [124-126]. Within the 
adipose microenvironment, the direct or indirect interactions between T cells and 
adipocytes may be multifaceted. Multiple cytokines and chemokines may 
regulate lymphocyte recruitment  to the WAT. One such protein known as 
regulated upon activation, normal T cell expressed and secreted (RANTES), 
which is secreted by murine and human adipocytes as well as stromal vascular 
fraction (SVF) cells [127], may promote the accumulation of lymphocytes into WAT 
via binding to their receptor CCR5. Similar to RANTES, the interaction between 
IFNγ inducible protein-10 (IP10), which is expressed by adipocytes [128], and its 
receptor CXCR3, which is present on T cells, can alter the balance between 
effector T cells and regulatory T cells (Tregs) [129]  and contribute to T cells 
recruitment into adipose tissue [130]. Furthermore, lymphocytes may modulate 
adipocyte cytokine secretion via the activation of the CD40–CD40L dyad and 
vice versa [131]. This possibility will be discussed in much detail later. 
         Distinct T cell subtypes play different roles in the course of obesity-related 
adipose tissue inflammation. T cells that express the surface marker CD8, 
referred to as effector, or cytotoxic T cells secrete proinflammatory cytokines. A 
study by Nishimura and colleagues has demonstrated that CD8+ T cell infiltration 
precedes that of macrophages during HFD feeding, and this T cell subset 
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promotes the recruitment and activation of ATMs [124]. In addition, overweight 
individuals contain a higher proportion of CD8+ cells in visceral adipose tissue 
compared with subcutaneous adipose tissue, and the percentage of CD8+ cells is 
positively correlated with the activity of caspase-1, which is a component of the 
NLR pyrindomain-containing 3 (NLRP3) inflammasome [132]. 
         T helper (TH) cells express the surface marker CD4 and can be divided into 
three subpopulations: TH1 cells, which produce proinflammatory cytokines (such 
as IFNγ); TH2 cells, which produce anti-inflammatory cytokines (such as IL-4, IL-
10 and IL-13) [133] and the recently identified IL-17-producing TH17 subpopulation 
[134].  In obesity, adipose tissue-associated lymphocytes undergo reorganization 
with the transition of small TH2 cell dominated repertoire (associated with lean 
phenotype) giving way to a much larger and more inflammatory TH1 and CD8+ 
cell dominated population [125]. This change leads to a progressively 
proinflammatory environment promoting insulin resistance. Compared with wild-
type mice, increased body weight and increased insulin resistance in RAG1-/- 
mice, which lack T lymphocytes, were reversed after adoptive transfer of CD4+, 
but not CD8+ T cells [125]. These results suggest that metabolic dysfunction 
caused by obesity is at least partially modulated by CD4+ cells, and that the 
imbalance between TH1 and TH2 cells in the WAT may represent a 
pathophysiological component of obesity and insulin resistance.  
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      Another CD4+ T cell population, Tregs, express forkhead-winged-helix 
transcription factor (Foxp3) and are characterized as CD4+/CD25+/Foxp3+ cells. 
Tregs secrete anti-inflammatory signals that inhibit macrophage migration and 
induce M2-like macrophage differentiation. These cells are considered to be 
important players in obesity-related adipose tissue inflammation. The number of 
adipose tissue Tregs decreases with obesity [126, 135, 136], whereas adoptive 
transfer of Tregs improves WAT inflammation and ameliorated insulin resistance 
in ob/ob mice [136, 137]. 
         Natural killer T (NKT) cells represent a heterogeneous T cell 
subpopulation with innate-like characteristics and are capable of producing both 
TH1 and TH2 cytokines [138]. The role of NKT cells in obesity-related inflammation 
is not entirely clear. On one hand, adoptive transfer of NKT cells improves 
nonalcoholic steatohepatitis and glucose intolerance in ob/ob mice [139]; on the 
other hand, NKT-deficient mice on HFD also display the same trend with reduced 
macrophage accumulation and better glucose tolerance compared with control 
mice [140]. Further investigations are required to elucidate the role of NKT cells in 
obesity-associated inflammation. 
        B cells can also accumulate in the WAT of HFD-fed obese mice [141]. Some 
studies have reported that B cells infiltrate into the WAT earlier than T cells or 
macrophages and prior to the appearance of insulin resistance [142]. B cell-
mediated effects on glucose metabolism are linked to proinflammatory 
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macrophages and T cell activation [143]. Furthermore, B cells can cause systemic 
insulin resistance through the production of pathogenic IgG autoantibodies [141]. 
 
1.4.3.3 Mast cells and Eosinophils 
        Mast cells are involved in early leukocyte recruitment and adaptive 
immunity via activation of antigen presenting dendritic cells. In response to 
different signals, mast cells can secrete a wide spectrum of biologically active 
products with either pro- or anti-inflammatory properties [144]. In 1963, Hellman 
and colleagues found that there were increased numbers of mast cells in both 
epididymal and subcutaneous adipose tissue of obese, diabetic mice, suggesting 
a potential role for mast cells in obesity [145].  This role of mast cells was 
confirmed by a recent study that described that genetic depletion or 
pharmacological stabilization of mast cells in mice reduced weight gain and 
ameliorated glucose homeostasis [114].  
        Eosinophils are associated with parasite immunity or allergy and can 
regulate obesity-associated adipose tissue inflammation by modulating 
macrophage polarization. This particular cell type was recently found to assist in 
glucose homeostasis by maintaining anti-inflammatory M2 macrophage content 
in WAT [146]. In this study, eosinophils within WAT were identified as the main 
source of IL-4 and IL-13, which contribute to the anti-inflammatory phenotype of 
macrophages. In the absence of eosinophils, M2 macrophages content was 
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greatly attenuated [146]. Interestingly, helminth-induced adipose tissue 
eosinophilia enhances glucose tolerance in HFD-fed obese mice [146].  
 
1.4.4 Anti-inflammatory therapies for metabolic diseases 
         Since chronic inflammation in obesity causes adverse metabolic effects in 
various tissues, it is natural to raise the question of whether therapeutic 
interventions that modulate inflammatory signaling cascades could have 
beneficial effects on metabolism. Several previous and ongoing studies have 
targeted inflammation at different points of the inflammatory pathway in obesity. 
       As described above, salsalate, a salicylate prodrug, suppresses IKKβ/NFκB 
activity and improves glycemic control as well as lipid parameters in type 2 
diabetic patients [147, 148]. Studies involving JNK antagonists, tested in mice, 
yielded positive results in glucose metabolism [149]. Inflammatory cytokines 
blockade also showed promising results on metabolic disease. Although anti-
TNF-α trials yielded conflicting results [150, 151], IL-1 receptor antagonists (anakinra) 
improved hyperglycemia and β-cell function and decreased systemic 
inflammatory markers [152]. Cell-based immunotherapy targeting obesity induced-
inflammation has recently attracted attention. Several animal studies 
demonstrated significant metabolic benefits because of depletion or stimulation 
of specific cell populations. For example, as discussed above, elimination of 
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CD11c+ immune cells or mast cells in obese mice yielded beneficial metabolic 
effects [114, 123].  
      These studies provide proof-of-principle that damping the inflammatory 
component of obesity results in improved insulin sensitivity in mice and humans. 
 
1.5 CD40-CD40L: a novel therapeutic target in obesity-induced adipose 
tissue inflammation? 
        Although the association between inflammation and obesity is extensively 
described in the literature as discussed earlier in this chapter, the nature and 
source of the early signals that initiate the proinflammatory phenotype in obese 
adipose tissue remain unknown. The exact immune cells that mediate adipose 
tissue inflammation and the spatial-temporal interplay between those different 
cell-types are unclear.  
        Two recent studies reported that major histocompatibility complex (MHC) 
class II expression in adipose tissue increased during the course of diet-induced 
obesity [153, 154]. One study indicated that ATMs can function as antigen 
presenting cells (APCs) [153], whereas the other study suggested that adipocyte 
MHC II is functional, therefore, adipocytes themselves can perform APC 
functions and induce antigen-specific CD4+ T cell activation via MHC II pathways 
[154].  
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1.5.1 T cell activation 
        T cells within adipose tissue are increasingly recognized to modulate 
adipose tissue inflammation and systemic inflammation [155]. It is generally 
assumed that the full activation of naïve T cells, including CD4+ T helper cells as 
well as CD8+ cytotoxic T cells, requires 3 signals. These signals involve both 
contact-dependent interactions through surface molecules and soluble factors 
like cytokines (Fig 1.10). 
 
 Signal 1, the initial signal, is the recognition by the T-cell receptor (TCR) 
of antigenic peptides presented by MHC II molecules. This signal alone 
often leads to T cell inactivation by anergy or deletion. 
 
 Signal 2 or co-stimulation is mainly provided by the interaction between 
co-stimulatory molecules that are expressed as receptors and ligands on 
the membrane of APC (B7/CD40) and the T cell (CD28/CD40L). Along 
with signal 1, signal 2 drives the T cell towards an activation state, which 
is characterized by sustained proliferation and the up-regulation of surface 
markers. 
 
 Signal 3 or polarization is transmitted by APCs and various inflammatory 
cytokines, which further enhance, modify, and skew T cell differentiation 
into different effector phenotypes.  
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Figure 1.10 Three signals for T cell activation 
The first signal involves T-cell receptor (TCR) triggering by donor antigen on APCs 
(Dendritic cells, macrophages etc.). The second signal or “costimulation signal” is 
delivered when CD80/86/40 on the surface of APCs engage CD28/CD40L on T-
cells.The third signal involves various cytokines resulting in T cell differentiation. 
 
 
 
 
3 
IL-12 
IFNα/β  
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1.5.2 The CD40-CD40L signaling pathway 
        Poggi et al. in 2009 [131] and Missiou et al. in 2010 [156], independently 
reported that the inflammatory receptor CD40 is expressed on the surface of both 
human and mouse adipocytes and that CD40 mRNA levels in adipose tissue 
were positively correlated with BMI [131]. The data presented in these two studies 
suggest that adipocytes do not passively but rather actively interact with 
lymphocytes, and that CD40 contributes to this crosstalk through direct cell-cell 
contact. These results have significant implications and suggest that CD40-
CD40L signaling may play a critical role and may be among the early signals that 
ignite inflammation in obesity. 
         CD40 was first discovered as an antigen expressed on human bladder 
carcinomas [157] and later in B lymphocytes [158]; however, subsequent studies 
demonstrated that CD40 is more ubiquitously expressed than what was initially 
thought. A list of cells expressing CD40 and the ligand of CD40, CD40L, is 
described in Table 1.2. The wide expression pattern of this co-stimulatory dyad 
indicates its broad roles in different physiological processes. 
        CD40 is a 48 kDa type I transmembrane glycoprotein cell surface receptor 
that belongs to the tumor necrosis factor receptor (TNFR) superfamily. Human 
CD40 contains a 193 amino acid (aa) extracellular domain, a 21-aa leader 
sequence, a 22-aa transmembrane domain, and a 62-aa intracellular domain [159]. 
CD40L, also known as CD154, gp39 or TNFSF5, is a member of the TNF 
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superfamily and is a  type II transmembrane protein, with variable molecular 
weight between 32 and 39kDa because of post-translational modifications [159].     
A soluble form of CD40L, sCD40L, which is mainly derived from activated 
platelets and activated T cells retains activities similar to its membrane-bound 
form [160]. 
          Unlike the insulin receptor described earlier in this chapter, the CD40 
cytoplasmic domain does not have intrinsic kinase activity. Similar to other 
members of the TNF receptor family, CD40 signaling is mediated in large part by 
a complex series of downstream events. The engagement of CD40 by CD40L 
leads to trimeric clustering of CD40 and the recruitment of adapter proteins 
known as TNFR-associated factors (TRAFs) to the cytoplasmic tail of CD40 [161].          
The cytoplasmic domain of CD40 contains a proximal binding site for TRAF6, 
and two distal sites that bind TRAF1, TRAF2, TRAF3 and, indirectly, TRAF5 (Fig 
1.11). Binding of the TRAFs results in the formation of a signaling complex that 
activates different pathways including the canonical (p50 dependent) and non-
canonical (p52 dependent) NFκB signaling pathways [162], p38/mitogen-activated 
protein kinases (MAPKs), c-Jun-NH2-kinase (JNK) as well as  phosphoinositide 
3-kinase (PI3K) signaling pathways [161, 163]. Independent of theTRAF-dependent 
signaling shown here, CD40 can also bind directly to Janus kinases 3 (JAK3). 
JAK3 binding induces the activators of a transcriptional program, for example, via 
the phosphorylation of signal transducer and activator of transcription 5 (STAT5) 
[164, 165].  
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Table 1.2 Expression of CD40 and CD40L in various cell types 
Cells CD40 CD40L Refs 
B cells + + [166-168] 
T cells + + [169-172] 
Monocytes and macrophages + + [173, 174] 
Dendritic cells + + [167, 175, 176] 
Neutrophils + - [177, 178] 
Mast cells + + [179] 
Platelets + + [180-182] 
Endothelial cells + + [183, 184] 
Fibroblast + - [167, 185] 
Smooth muscle cells + + [184, 186] 
Adipocytes + - [131, 156, 187] 
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Figure 1.11 The CD40 signaling pathway 
The interaction between CD40 and CD40L causes a conformational change that recruits 
adapter molecules known as TNF receptor associated factors (TRAF) to the binding 
sites on the CD40 cytoplasmic tail. TRAFs then recruit TRAF-interacting kinases and 
together influence a number of signal transduction pathways, including the nuclear 
factor-κB, p38/mitogen-activated protein kinase (MAPK), and c-Jun-NH2-kinase (JNK) 
pathways. Target genes of CD40 signaling regulate apoptosis, cell cycle progression, 
cytokine production, expression of cell surface immune modulators, and TNF family 
members and other pathways 
Adapted from Clin Cancer Res. 2007 Feb 15;13(4):1083-8 
51 
 
 
           Taken together, these complex pathways elicit essential signals that are 
mediated through CD40 to regulate diverse cellular processes including 
apoptosis, cell cycle progression, inflammatory chemokine and cytokine 
production, dendritic cell survival and prolonged MHC/antigen complex 
presentation. 
         It is now clear that CD40-CD40L signaling regulates antibody production 
and T cell function through processes that involve T helper cells, APCs, and 
circulating B cells. The in vivo critical role of CD40-CD40L in regulating immunity 
is emphasized by the finding that mutations in either CD40L or CD40 gene cause 
hyper IgM syndrome (HIGM) in patients, termed HIGM1 and HIGM3, respectively 
[188]. HIGM is characterized by increased susceptibility to opportunistic pathogens, 
such as Pneumocystis carinii and Cryptosporidium [189, 190] and by elevated 
concentrations of serum IgM with very low levels of IgG, IgA and IgE [191, 192]. 
Similar deficiencies in mounting immune responses were observed in genetically 
modified CD40L-/- [193, 194] and CD40-/- mice [195, 196]. 
          To date, much is known about the consequences that defective CD40-
CD40L interactions have on the immune system. In contrast, very little is known 
about the exact role of CD40 signaling in non-hematopoietic cell types. 
Increasing evidence from experimental and clinical studies has suggested a 
complex but not fully elucidated role of CD40-CD40L signaling in regulating the 
pathogenesis of obesity, type 2 diabetes and vascular complications. For 
example, the interaction between CD40 and CD40L triggers a cascade of events 
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that are involved in early and late stages of atherosclerosis [197] and sCD40L 
levels may predict risk for major cardiovascular events, including acute 
myocardial infarction and sudden cardiac death [198, 199].  In addition, Lutgens and 
colleagues indicate that absence of CD40L-CD40-TRAF6 signaling abolished 
atherosclerosis by skewing the immune response towards an anti-inflammatory 
profile [200]. Furthermore, Poggi et al. demonstrated that CD40 mRNA levels in 
adipose tissue and plasma levels of CD40L positively correlated with BMI [131].  
CD40 is expressed on adipocytes as well as immune cells in adipose tissue SVF 
and CD40L exposure reduces insulin mediated glucose uptake by adipocytes. 
These data suggest that resident or infiltrated T cells in obese adipose tissue 
may directly induce adipocyte inflammation and impair adipose tissue insulin 
sensitivity, thereby contributing to systemic inflammation [131].  
         The therapeutic potential of targeting the CD40-CD40L signaling axis to 
reduce the deleterious effects of inflammation has been extensively investigated 
in multiple diseases involving acute inflammation, such as atherosclerosis, 
inflammatory bowel disease, psoriasis, rheumatoid arthritis, allograft rejection 
and type I diabetes [201].  However, whether this strategy can be applied to the 
treatment of complications like chronic low-grade inflammation in obesity and 
type 2 diabetes remains unanswered. Importantly, because costimulation 
blockade interrupts an effective immune response, long-term CD40-CD40L 
signaling interventions will not be without risk of immune-suppression, therefore it 
is crucial to understand the detailed molecular mechanism of CD40-CD40L 
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signaling in the pathophysiology of obesity to fine tune this signaling pathway 
meticulously. 
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Chapter II 
 
CD40 Deficiency Exacerbates Obesity-induced Adipose Tissue 
Inflammation, Hepatic Steatosis, and Insulin Resistance in Mice 
 
Chapter contents 
2.1 Introduction 
2.2 Materials and Methods  
2.3 Results 
2.3.1 CD40-/- mice display decreased weight, food intake and physical 
                activity 
     2.3.2 CD40 deficiency exacerbates diet-induced insulin resistance 
     2.3.3 CD40-/- mice develop hepatic steatosis and increased de novo 
               lipogenesis in the liver 
 2.3.4 CD40-/- mouse livers are insulin resistant despite decreased 
          Inflammation 
 2.3.5 CD40-/- mice exhibit increased basal lipolysis in the adipose tissue 
 2.3.6 CD40 depletion increases adipose tissue inflammation 
 2.3.7 CD40-/- mice have increased cytotoxic T cell content in the adipose 
          tissue 
2.3.8 CD40-/- mice have increased eosinophil, B cell, NK/NKT cell infiltration in 
         adipose tissue 
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2.1 Introduction 
        Obesity is often associated with type 2 diabetes [202, 203], hepatic steatosis, 
NASH [204], cardiovascular complications [205, 206] and certain cancers [207, 208]. 
When nutrient supply exceeds demand, adipocytes expand by hypertrophy and 
hyperplasia to store excess fat in the form of triglycerides. As adipocytes 
increase in size, their ability to store fat is diminished and fatty acids are 
ectopically deposited in the liver and muscle [209, 210]. This transition of lipid 
handling is thought to cause lipotoxicity in these peripheral tissues, disrupting 
insulin signaling. Glucose uptake by skeletal muscle in response to insulin is 
impaired in this condition and hepatic gluconeogenesis is elevated, leading to 
glucose intolerance. 
        Adipose tissue in obese rodents and humans has the hallmarks of chronic 
inflammation, including the involvement of T cells, macrophages and other 
immune cells [124, 126, 140, 142, 211]. During the progression to obesity, immune cells 
and the factors they secrete interact with adipocytes and alter the ability of 
adipose tissue to store fat in response to insulin. Inflammation has been 
described in obese fat [90], liver [86], and muscle [212], the three key insulin target 
tissues. Importantly, it has been shown that decreasing inflammation with either 
genetic manipulation in rodents or pharmacologic inhibition of key mediators of 
inflammation in humans [74, 213], improves insulin sensitivity. Although the 
association between obesity and inflammation is extensively described, the exact 
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mechanisms for initiation of inflammation are unknown and the spatial and 
temporal actions of the cells involved are unclear. 
         The CD40-CD40L costimulatory dyad plays a critical role in regulating 
innate and adaptive immune responses. CD40 is a 48-kDa transmembrane 
glycoprotein cell surface receptor that belongs to the tumor necrosis factor 
receptor (TNFR) superfamily and is activated by binding to its ligand CD40L [214]. 
Various immune cells including macrophages, B lymphocytes, T cells, dendritic 
cells and mast cells, as well as smooth muscle cells, endothelial cells and 
activated platelets express CD40 [215]. Recent evidence indicates that the CD40-
CD40L complex is also a potential mediator of chronic inflammation in obesity 
and its related metabolic disorders [131, 156, 187, 216], suggesting a broader role of 
CD40 in cell biology. Obese and diabetic individuals have higher levels of active 
sCD40L in the circulation compared to lean healthy subjects [217]  and CD40 
mRNA levels in WAT were found to positively correlate with BMI [131]. Interruption 
of CD40 signaling has been shown to limit experimental autoimmune diseases in 
mice such as arthritis, lupus nephritis, multiple sclerosis and thyroiditis and 
treatment of hyperlipidemic mice with an anti-CD40L antibody reduced the 
number of macrophages, T cells and inflammatory markers in atherosclerotic 
lesions [218]. Currently, targeting CD40-CD40L signaling is considered to be a 
promising strategy for effecting plaque stabilization in the treatment of 
atherosclerosis [219]. 
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        On the basis of the above considerations, we anticipated that suppression 
of the CD40-CD40L signaling cascade would also reduce the deleterious 
inflammation and metabolic effects associated with obesity. In fact, the CD40-
CD40L axis has recently been implicated in the pathogenic complications of 
obesity [220-222]. However, various research groups have reported conflicting roles 
of CD40L in diet-induced obesity in mice. For example, two studies showed that 
CD40L deficiency aggravated hepatic steatosis in obesity [221, 222], whereas 
another study indicated that the absence of CD40L attenuated diet-induced 
steatosis [220]. Furthermore, in one study, CD40L deficiency improved insulin 
resistance [220], whereas in another study lack of CD40L in mice did not 
ameliorate HFD induced insulin resistance [222].  A caveat in these studies is that 
CD40L can mediate inflammation through CD40-independent mechanism by 
interacting directly with Mac-1/CD11b, which is expressed abundantly on 
macrophages and monocytes [223]. We therefore designed the present studies to 
specifically evaluate the role of the CD40-CD40L dyad in adipose tissue 
inflammation, insulin resistance and hepatic steatosis associated with diet-
induced obesity. Here we evaluated the effects of depletion of CD40 itself in mice, 
which has not been yet reported. Surprisingly, we found that CD40 knockout 
(CD40-/-) mice paradoxically displayed significantly higher levels of adipose tissue 
inflammation, impaired glucose tolerance and remarkable hepatic steatosis 
without liver inflammation. These results suggest an unexpected primary role for 
CD40 in attenuating immune cell recruitment to the visceral adipose tissue during 
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the progression of diet-induced obesity. This in turn reduces adipocyte lipolysis, 
thereby protecting the liver from the increased influx of lipid from adipose tissue 
and enhancing whole body glucose tolerance. 
 
2.2 Materials and Methods 
2.2.1 Animal studies 
       Male CD40-/- (B6.129P2-Cd40tm1Kik/J) and control C57BL/6J mice were 
obtained from the Jackson Laboratory (Bar Harbor, ME). The background strain 
of B6.129P2-Cd40tm1Kik/J mice in this study is C57BL/6Ncr, which is maintained 
by the Jackson Laboratory via sibling mating (34 generations as of Nov, 2008). 
Since the C57BL/6Ncr mouse line from NIH has been separated from the 
B6.129P2-Cd40tm1Kik/J mice for many generations, we created littermate control 
animals for this study to avoid potential genetic drift from various C57BL/6Ncr 
substrains or colonies. We bred B6.129P2-Cd40tm1K k/J mice with C57BL/6J mice 
and then their F1 hybrids were used to generate knockout and wild-type 
littermates. All animals were fed a standard chow diet (LabDiet PicoLab 5053; 
Purina Mills, St. Louis, MO) until 8 weeks of age and then were divided into two 
groups; one was fed chow diet and the other group a HFD (TD.93075, 55/Fat, 
Harlan Teklad, Madison, WI, fatty acid profile as % total fat: 28% saturated, 30% 
trans, 28% monounsaturated cis, 14 % polyunsaturated cis). Animals were 
housed in the University of Massachusetts (UMass) Medical School Animal 
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Medicine facility with a 12:12-h light-dark cycle and given ad libitum access to 
food and water. Mice and food were weighed weekly over the duration of the 
study.  
         Intraperitoneal glucose tolerance test (GTT), insulin tolerance test (ITT) and 
pyruvate tolerance test (PTT) was performed as previously described [224]. Briefly, 
after a 16-hour overnight fast, GTTs or PTTs were performed with intraperitoneal 
(i.p.) injection of 10% w/v D-glucose in sterile water (1 g glucose/kg body weight). 
Whole blood glucose values were measured using Ascencia Breeze glucose 
monitors (Bayer Healthcare Diabetes Care Division, Tarrytown, NJ) before and 
after the indicated times post challenge/injection. ITTs were similarly performed 
with i.p. injection of recombinant human insulin (1 U insulin/kg body weight; 
Novolin R, Novo Nordisk Inc, Princeton, NJ) following a shorter fast period of 4-
hour and blood glucose measurements were done at the indicated times before 
and post challenge/injection. Composition of total fat and lean mass was 
assessed by 1H-MRS-based body composition analysis (EchoMRI-3in1TM, 
EchoMRI, Houston, TX). Measurements of energy expenditure, respiratory 
exchange ratio, indirect calorimetry and physical activity using metabolic cages 
(TSE Systems, Bad Homburg, Germany) were done by the UMass Mouse 
Metabolic Phenotyping Center. All experiments were performed in accordance 
with protocols approved by the Institutional Animal Care and Use Committees 
(IACUC) at UMass Medical School. 
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2.2.2 Hyperinsulinemic-euglycemic clamp studies 
        The clamp study was performed at the UMass Mouse Metabolic 
Phenotyping Center. Mice fed HFD for 16 weeks were subject to an overnight 
fast (~15 hours), and a 2-hour hyperinsulinemic-euglycemic clamp was 
conducted in awake mice with a primed and continuous infusion of human insulin 
(150 mU/kg body weight priming followed by 2.5 mU/kg/min; Humulin; Eli Lilly). 
During the clamp, 20% glucose was infused at variable rates to maintain 
euglycemia [225]. Whole body glucose turnover was assessed with a continuous 
infusion of [3-3H] glucose and 2-deoxy-D-[1-14C] glucose (PerkinElmer, Waltham, 
MA) was administered as a bolus (10 μCi) at 75 min after the start of clamps to 
measure insulin-stimulated glucose uptake in individual organs. At the end of the 
study, mice were anesthetized, and tissues were taken for biochemical analysis. 
 
2.2.3 Hepatic triglyceride analyses 
        Hepatic triglyceride content measurement was performed as previously 
described [226]. Mice were fasted for 4 hours; total lipids were extracted from liver 
samples (50 mg), using a 2:1 mixture of chloroform and methanol. The organic 
layer was dried overnight and reconstituted in a solution containing 60% butanol 
and 40% of a 2:1 mixture of Triton-X114 and methanol. Colorimetric analyses 
were used to measure total triglyceride (Wako Diagnostics, Richmond, VA). 
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2.2.4 Histology 
        Liver, pancreas, and epididymal WAT were dissected and fixed by 
immersion in 10% neutral buffered formalin (Sigma, St. Louis, MO) for 12 hours, 
dehydrated, cleared and then embedded in paraffin. Sections (7 μm) were 
stained with hematoxylin and eosin to assess morphology. Pancreatic islets were 
stained with insulin antibody (Cell Signaling, Danvers, MA). Oil red O (Sigma) 
was used to stain neutral lipids in frozen liver sections.  
 
2.2.5 Real-Time quantitative RT-PCR 
        RNA was extracted from homogenized liver and adipose tissue using the 
TRIzol Reagent according to manufacturer’s instructions (Invitrogen, Carlsbad, 
CA). Complementary DNA was synthesized from 1 µg of total RNA using iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA). For real-time PCR, synthesized 
cDNA, forward and reverse primers along with the iQ SYBR Green Supermix 
were run on the CFX96 real-time PCR system (Bio-Rad). Primer sequences are 
listed in Table 2.1. Fold change in mRNA expression was determined using the 
2-ΔΔCT method, with all genes normalized to the ribosomal mRNA 36B4.  
 
2.2.6 Western Blotting 
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       Tissue pieces were homogenized in S-50 protein lysis buffer (20 mM Tris 
[pH 7.2], 1% Triton X-100, 100 mM NaCl, 1 mM EDTA, 25mM sodium fluoride, 1 
mM sodium orthovanadate, 1mM benzamidine, 1 mM phenylmethylsulfonyl 
fluoride, and 10 μg/mL of aprotinin and leupeptin) in gentleMACS M tubes 
(Miltenyi Biotec, Germany). Protein was quantified using a BCA protein assay kit 
(Thermo Scientific, Waltham, MA), resolved on a 10% SDS-PAGE gel, 
transferred to a nitrocellulose membrane, blocked with 5% nonfat milk in TBST 
(0.05% Tween 20 in Tris-buffered saline), washed with TBST, and incubated with 
primary antibody overnight. The blots were washed with TBST, and a 
horseradish peroxidase secondary antibody was applied. Proteins were 
visualized using Western Lightening Plus ECL (PerkinElmer, Waltham, MA). 
Primary antibodies used were phospho-Akt (Ser473) and total Akt (Cell Signaling, 
Danvers, MA).  
 
2.2.7 Ex vivo Lipolysis Assay in epididymal adipose tissue- explants 
         Epididymal fat pads were surgically removed from male mice and washed 
with ice-cold PBS. Fat pads (~100mg, n=4/mouse) were preincubated for 1 hour 
in 140 µl of DMEM (Life Technologies) containing 2% fatty acid-free serum 
albumin (Sigma-Aldrich). Subsequently, fat pads were incubated in 250 µl of 
KRH buffer (125 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, 5 mM 
HEPES, pH 7.2) plus 2% BSA (fatty acid free) with or without the presence of 
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isoproterenol (10 µM) for 2 hours at 37°C. Free glycerol content was quantified 
for each sample in the medium using the Free Glycerol Determination Kit (Wako 
Diagnostics).  Glycerol release from each sample was normalized to the weight 
of each fat pad.  
 
2.2.8 Flow cytometry 
         Epididymal adipose tissue was isolated from mice and treated with 2 
mg/mL collagenase (Sigma) for 45 minutes at 37oC. Digested tissue was filtered 
through a 200 μM nylon mesh and then centrifuged at 1000 rpm for 10 min.  
Pelleted SVF of adipose tissue was stained with fluorescently conjugated primary 
antibodies according to manufacturers’ instructions. Primary antibodies used 
were CD4-FITC (BD Pharmingen cat. no. 553046), CD3-APC-Cy7 (BD 
Pharmingen cat. no.1452C11), CD25-APC (eBiosciences cat. no. 17-0251-81), 
CD8a-PerCP-Cy5.5 (BD Pharmingen cat. no. 551162), CD90-PE-Cy7 (BD 
Pharmingen cat. no.  561558), CD11b-PerCP-Cy5.5 (BD Pharmingen cat. no. 
562127), F4/80-APC (ABD Serotec), NK1.1-APC (eBiosciences cat. no. 17-5941), 
CD19-Alexa 405 (BD Pharmingen cat. no.  560375), and FoxP3-PE 
(eBiosciences cat. no. 12-4774). Samples were run on a BD LSRII flow 
cytometer (BD Biosciences, San Jose, CA) and analyzed in FlowJo (TreeStar).  
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2.2.9 ELISA assay 
         Blood was obtained from the tail veins of mice or via cardiac puncture and 
allowed to clot. Serum was isolated by centrifugation at 1000g for 10 min.  Mouse 
insulin ELISA kit (EMD Millipore, Billerica, MA) and Mouse sCD40L Platinum 
ELISA kit (eBioscience, San Diego, CA) were used to measure serum insulin and 
sCD40L as recommended by the manufacturer. 
 
2.2.10 Vascular permeability assay 
         Evans blue dye (5 mg/ml in PBS; Sigma-Aldrich) was injected into the tail 
vein of mice at the dose of 25 mg/kg. After one hour of complete circulation of the 
dye, the mice were euthanized by CO2 inhalation and were perfused with 30 ml 
warm PBS via the left ventricle to remove the Evans blue dye from the 
vasculature. Visceral adipose tissues were surgically removed, blotted dry, and 
weighed. The Evans blue dye was extracted from the fat tissue with 1 ml of 
formamide overnight at 55°C and measured spectrophotometrically at 620 nm.  
The optical density (OD) value was transformed into the concentration according 
to a standard curve of Evans blue dye. 
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2.2.11 Statistical Analysis 
        Differences between groups were examined for statistical significance using 
the two-tailed Student's test or analysis of variance (ANOVA) followed by post 
hoc Bonferroni tests. The data are presented as the means ± S.E.M. P-values ≤ 
0.05 were considered significant.   
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Table 2.1 Primers for Real-Time Quantitative RT-PCR 
 
36B4 Forward: TCCAGGCTTTGGGCATCA 
Reverse:  CTTTATCAGCTGCACATCACTCAGA 
C/EBPα Forward: CAAGAACAGCAACGAGTACCG 
Reverse:  GTCACTGGTCAACTCCAGCAC 
C/EBPβ Forward: CTGAGCGACGAGTACAAGAT  
Reverse: CTGCTTGAACAAGTTCCG 
PPARγ Forward: TCGCTGATGCACTGCCTATG 
Reverse:  GAGAGGTCCACAGAGCTGATT 
SREBP-1c Forward: CATCAACAACCAAGACAGTC 
Reverse:  CCAGAGAAGCAGAAGAGAAG 
ChREBP Forward: AGATGGAGAACCGACGTATCA 
Reverse: ACTGAGCGTGCTGACAAGTC 
LXRα Forward: CTCAATGCCTGATGTTTCTCCT 
Reverse: TCCAACCCTATCCCTAAAGCAA 
FASN Forward: GGAGGTGGTGATAGCCGGTAT 
Reverse:  TGGGTAATCCATAGAGCCCAG 
ACC1 Forward: ATGGGCGGAATGGTCTCTTTC 
Reverse: TGGGGACCTTGTCTTCATCAT 
SCD1 Forward: TTCTTGCGATACACTCTGGTGC 
Reverse: CGGGATTGAATGTTCTTGTCGT 
ACSL1 Forward: TGCCAGAGCTGATTGACATTC 
Reverse:  GGCATACCAGAAGGTGGTGAG 
ACSL4 Forward:  CTCACCATTATATTGCTGCCTGT 
Reverse:  TCTCTTTGCCATAGCGTTTTTCT 
ACCβ Forward: CGCTCACCAACAGTAAGGTGG 
Reverse:  GCTTGGCAGGGAGTTCCTC 
ACOT3 Forward:  GGAATTGGAAGTGGCCTTCTG 
Reverse:  TCCATGTCCTTAGGGAGGTCC 
DGAT1 Forward:  TCCGTCCAGGGTGGTAGTG 
Reverse:  TGAACAAAGAATCTTGCAGACGA 
DGAT2 Forward: GCGCTACTTCCGAGACTACTT 
Reverse: GGGCCTTATGCCAGGAAACT 
DYK Forward: TGAACCTGAGGATTTGTCAGC 
Reverse:  CCATGTGGAGTAACGGATTTCG 
MTTP Forward: CTCTTGGCAGTGCTTTTTCTCT 
Reverse:  GAGCTTGTATAGCCGCTCATT 
ICAM1 Forward: GTGATGCTCAGGTATCCATCCA 
Reverse: CACAGTTCTCAAAGCACAGCG 
VCAM1 Forward: AGTTGGGGATTCGGTTGTTCT 
Reverse: CCCCTCATTCCTTACCACCC 
NLRP3 Forward: ATTACCCGCCCGAGAAAGG 
Reverse: TCGCAGCAAAGATCCACACAG 
F4/80 Forward: CCCCAGTGTCCTTACAGAGTG 
Reverse:  GTGCCCAGAGTGGATGTCT 
CD68 Forward:  GGACCCACAACTGTCACTCA 
Reverse:  AAGCCCCACTTTAGCTTTACC 
CD11b Forward: CCATGACCTTCCAAGAGAATGC 
Reverse: ACCGGCTTGTGCTGTAGTC 
CD11c Forward: CTGGATAGCCTTTCTTCTGCTG 
Reverse: GCACACTGTGTCCGAACTCA 
MGL1 Forward: TGAGAAAGGCTTTAAGAACTGGG 
Reverse:  GACCACCTGTAGTGATGTGGG 
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CD3γ Forward: ACTGTAGCCCAGACAAATAAAGC 
Reverse:  TGCCCAGATTCCATGTGTTTT 
IFNγ Forward: ATGAACGCTACACACTGCATC 
Reverse:  CCATCCTTTTGCCAGTTCCTC 
TNFα Forward: TCAGCCGATTTGCTATCTCATA 
Reverse:  AGTACTTGGGCAGATTGACCTC 
IL-1β Forward: GCAACTGTTCCTGAACTCAACT 
Reverse: ATCTTTTGGGGTCCGTCAACT 
Cidea Forward: ATCACAACTGGCCTGGTTACG 
Reverse:  TACTACCCGGTGTCCATTTCT 
FSP27 Forward: ATCAGAACAGCGCAAGAAGA 
Reverse:  CAGCTTGTACAGGTCGAAGG 
IL-6 Forward: TAGTCCTTCCTACCCCAATTTCC 
Reverse:  TTGGTCCTTAGCCACTCCTTC 
CD40 Forward: TTGTTGACAGCGGTCCATCTA 
Reverse: GCCATCGTGGAGGTACTGTTT 
CD154 Forward: CCTTGCTGAACTGTGAGGAGA 
Reverse: CTTCGCTTACAACGTGTGCT 
SAA2 Forward: TGGCTGGAAAGATGGAGACAA 
Reverse:  AAAGCTCTCTCTTGCATCACTG 
CD4 Forward: CTAGCTGTCACTCAAGGGAAGA 
Reverse:  CGAAGGCGAACCTCCTCTAA 
CD8α Forward: CCGTTGACCCGCTTTCTGT 
Reverse:  TTCGGCGTCCATTTTCTTTGG 
vWF Forward: CTTCTGTACGCCTCAGCTATG 
Reverse:  GCCGTTGTAATTCCCACACAAG 
CD31 Forward: CTGCCAGTCCGAAAATGGAAC 
Reverse: CTTCATCCACCGGGGCTATC 
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2.3 Results 
2.3.1 CD40-/- mice display decreased weight, food intake and physical 
activity 
        To investigate the role of CD40 in diet-induced obesity, CD40-/- mice and 
wild type (WT) controls were put on feeding regimens consisting of a HFD or a 
normal diet (ND). The CD40-null mice were found to be ~2 grams lighter than 
control mice on either diet throughout most of a 14-week feeding period (Figure 
2.1A). These data are consistent with a previous study on CD40L-/- mice [220], 
suggesting a common role for CD40 and CD40L in the regulation of energy 
homeostasis. Food intake of CD40-/- mice was significantly lower on HFD (Figure 
2.1B), potentially explaining in part the decreased body weight (Figure 2.1A). 
Physical activity measurements on mice fed the HFD over a 24-hour period 
indicated that CD40-/- mice were significantly less active than WT mice at 8 and 
14 weeks of age (0 and 6 weeks on HFD)  (Figure 2.1C). However, respiratory 
exchange ratio (RER) (Figure 2.2A) and energy expenditure (Figure 2.2B) were 
not significantly different between the two groups of mice.  
 
2.3.2 CD40 deficiency exacerbates diet-induced insulin resistance 
         Decreased weight, food intake and activity in CD40-/- mice suggested a role 
for CD40 in whole body metabolism. To characterize this role, we did a series of  
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Figure 2.1 CD40 deficiency alters energy homeostasis 
(A) Growth curve of mice fed either normal diet (ND) or high-fat diet (HFD) for a period of 
14 weeks (n = 12), * indicates statistically significant difference between WT ND vs 
CD40-/- ND groups or WT HFD vs. CD40-/- HFD groups. (B) Daily food intake of mice (n 
= 12) fed ad libitum on ND or HFD for a period of 13 weeks. (C) Ambulatory activity as 
estimated by infrared beam breaks over a 24-hour period for mice on HFD for 0, 6, 12 or 
16 weeks (n = 6). Data presented are mean ± S.E.M. Statistically significant differences 
are indicated * P<0.05, ** P<0.01 vs. control. 
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Figure 2.2 Respiratory exchange ratio and Heat production of mice on HFD 
A) Respiratory exchange ratio as of 0,6,12, and 16 weeks on HFD 
B) Heat production as of 0,6,12, and 16 weeks on HFD  
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metabolic analyses on these mice, including a hyperinsulinemic-euglycemic 
glucose clamp study. CD40-/- mice on HFD showed a reduced steady-state 
glucose infusion rate (GIR) (Figure 2.3A), suggesting that the absence of CD40 
aggravates systemic insulin resistance in obesity. We also observed decreased 
2-deoxy-[14C] glucose uptake in the brown adipose tissue (BAT) of CD40-/- mice 
with no changes of glucose uptake in the WAT or muscle (Figure 2.3B). The 
morphology of pancreatic islets (Figure 2.4), fasting serum insulin, serum 
sCD40L, serum triglycerides and free fatty acids (FFA) were similar in both 
CD40-/- and WT mice on HFD (Figure 2.5). To further analyze the metabolic 
phenotype of the CD40-/- mice, we subjected them to a GTT as well as an ITT. 
Despite the reduced body weight of CD40-/- mice on HFD, they exhibited glucose 
intolerance (Figure 2.6 A and E) and insulin resistance (Figure 2.6 B and F) 
compared to WT controls. To assure these phenotypes we observed are due to 
CD40 deficiency and not due to the potential differences in mouse colonies or 
sub-strains, we created CD40-/- mice and WT littermate control mice by breeding 
the F1 hybrids of CD40-/- (B6.129P2-Cd40tm1Kik/J) and C57BL6/J parental mice. 
These cohorts were also subjected to GTT (Figure 2.6 C and G) and ITT tests 
(Figure 2.6 D and H). Similar to our original findings, the CD40-/- mice were 
significantly more glucose intolerant and insulin resistant than littermate control 
animals.   
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Figure 2.3 Hyperinsulinemic-euglycemic clamp analysis on mice fed HFD 
(A) Steady-state glucose infusion rate (GIR) for WT and CD40-/- mice on HFD for 16 
weeks to maintain euglycemia during hyperinsulinemic-euglycemic clamps (n = 10). (B) 
2-deoxy-[14C] glucose uptake in visceral WAT, gastrocnemius muscle (Skeletal Muscle), 
intrascapular brown adipose tissue (BAT), and heart. Data presented are mean ± S.E.M. 
Statistically significant differences are indicated     * P<0.05, ** P<0.01 vs. control. 
A 
B 
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Figure 2.4 Morphology of pancreatic islets in CD40-/- and wild-type mice 
Pancreatic islets were stained with insulin antibody (Brown) 
(A) WT on ND and HFD 
(B) CD40-/- on ND and HFD 
 
 
 
A 
B 
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Figure 2.5 Fast serum insulin, sCD40, triglyceride (TG), and Free fatty acid 
(FFA) in HFD fed CD40-/- and wild-type mice 
 
 
 
A 
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Figure 2.6 CD40-/- mice fed HFD are more glucose intolerant and insulin resistant 
(A) Glucose tolerance test (GTT) for CD40-/- and C57BL/6J control mice (30-week old) on HFD 
for 22 weeks (n=8). Animals were fasted overnight and glucose was injected intraperitoneally at a 
dose of 1g/kg of body weight.  (B) Insulin tolerance test (ITT). 31-week old CD40-/- and C57BL/6J 
control mice on HFD for 23 weeks (n=8) were fasted for 4 hours and injected with insulin at a 
dose of 1U/kg. (C) GTT for CD40-/- and littermate control mice (18-week old) on HFD for 10 
weeks (n=4). Animals were fasted overnight and glucose was injected intraperitoneally at a dose 
of 1g/kg of body weight.  (D) ITT; 18-week old CD40-/- and littermate control mice on HFD for 10 
weeks (n=4) were fasted for 4 hours and injected with 1U/kg insulin. (E) Area under the curve 
(AUC) for A. (F) AUC for B. (G) AUC for C. (H) AUC for D. Data are presented as mean ± SEM. 
Statistically signiﬁcant differences between WT HFD and CD40-/- HFD groups are indicated  *P < 
0.05, ** P< 0.01, ***P<0.001). 
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2.3.3 CD40-/- mice develop hepatic steatosis and increased de novo 
lipogenesis in the liver 
         Recent literatures have implicated CD40L as a protective factor against 
hepatic steatosis [221, 222], which has a strong association with insulin resistance 
[227]. Since we found impaired systemic insulin sensitivity in CD40-/- mice, we 
evaluated the hepatic steatosis and hepatic insulin sensitivity in these mice. No 
difference was observed in lipid content of livers of CD40-/- mice fed ND (Figure 
2.7C) compared with WT controls on the same diet (Figure 2.7A). However, 
CD40-/- mice on HFD displayed clearly steatotic livers, as observed both 
macroscopically and microscopically by H&E or Oil-red O staining (Figure 2.7D 
vs 2.7B). To quantify this increased steatosis, we measured total hepatic 
triglyceride levels and found a 59% increase in CD40-/- mice (Figure 2.7E). 
Elevated expression of two lipid droplet proteins, cell death-inducing DFFA-like 
effector A (CIDEA) and Fat Specific Protein 27 (FSP27) [228, 229], accompanied the 
increase in total triglycerides in the liver (Figure 2.7F). These lipid droplet 
proteins are specifically expressed in steatotic livers and are absent in lean livers 
(Figure 2.7F). Increased hepatic steatosis could be mediated by different 
pathways including increased dietary lipid absorption, increased de novo 
lipogenesis, the increased influx of nonesteriﬁed FFAs from hypertrophied 
adipose tissue, or decreased very low density lipoprotein (VLDL) secretion and 
fat oxidation [62, 230]. As no difference in plasma FFAs, respiratory exchange ratio 
and heat production were observed between CD40-null and WT mice (Figure 2.2  
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Figure 2.7 CD40 protects against diet-induced hepatic steatosis 
(A-D) Macroscopic (top left insets) and microscopic examination of WT and CD40-/- 
mouse livers on ND or 24-week HFD. Representative sections are stained with 
hematoxylin-eosin or Oil red O (bottom left insets) (Magnification: 200X). (E) Hepatic 
total triglycerides in WT and CD40-/- mice fasted for 6 hours (n=6). (F) Gene expression 
of lipid droplet proteins Cidea and FSP27 in the livers of WT and CD40-/- mice (n=6) was 
measured by qRT-PCR. Data are presented as mean ± SEM. Statistically signiﬁcant 
differences between group WT HFD and CD40-/- HFD are indicated: *P < 0.05, ** P< 
0.01. 
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and Figure 2.5), a role for increased dietary fat absorption or impaired fat 
oxidation is unlikely the cause of the hepatic steatosis in CD40-/- mice. Therefore, 
we measured the expression of transcription factors that promote hepatic 
lipogenesis as well as genes that encode enzymes contributing to lipogenesis. 
Peroxisome proliferator-activated receptor gamma (PPARγ) and sterol-regulatory 
element-binding protein-1c (SREBP1-c), two key regulators of hepatic 
lipogenesis, were both significantly elevated in the CD40-/- mice fed the HFD 
(Figure 2.8A). Acetyl-CoA carboxylase-2 (ACC2) and long-chain fatty-acid-CoA 
ligase-1 (ACLS1) are genes both involved in de novo lipogenesis, and were both 
increased in CD40-/- mice (Figure 2.8B). These data suggest that the hepatic 
steatosis observed in CD40-/- mice is probably due to an increased de novo 
lipogenesis. 
 
2.3.4 CD40-/- mouse livers are insulin resistant despite decreased 
inflammation  
        Since hepatic steatosis is correlated with hepatic insulin resistance in 
mouse and human obesity, we tested the hypothesis that CD40-/- mice on HFD 
had greater hepatic insulin resistance. We injected mice intraperitoneally with 
insulin (1mU/g) and measured Akt phosphorylation at Ser473 as an indicator of 
hepatic insulin signaling. Compared with WT controls, CD40-/- mice on HFD for 
24 weeks exhibited 45% lower Ser473 phosphorylation on immunoblot  
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Figure 2.8 CD40 deficiency enhances hepatic lipogenesis 
(A) Expression of genes that encode lipogenic transcription factors and coactivators 
(C/ebpα, C/ebpβ, Pparγ, Srebp1c, Chrebp and Lxr) in livers of HFD fed WT and CD40 -/- 
mice (n=6). (B) Expression of genes that encode enzymes (Fasn, Acc1/2, SCD1, Acsl1/4, 
Dgat1/2, Gyk, Mttp) that promote lipogenesis in livers of HFD fed WT and CD40 -/- mice 
(n=6). Data are presented as mean ± S.E.M. Statistically signiﬁcant differences between 
group WT HFD and CD40-/- HFD are indicated: *P < 0.05, ** P< 0.01). 
A 
B 
80 
 
 
 
 
Figure 2.9 CD40 deficiency exacerbates hepatic insulin resistance. 
(A) Hepatic Akt activation following acute insulin injection (1U/kg i.p., 10 min).  Western 
blot analysis of liver extracts showing phosphor-(Ser473) AKT (pAkt) levels under control 
(PBS, indicated as “-”) and insulin (“+”) treated conditions. (B) densitometric quantitation 
of pAkt/Akt ratios (n=6). Data are presented as mean ± S.E.M. Statistically signiﬁcant 
differences between groups WT HFD and CD40-/- HFD are indicated *P < 0.05. 
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densitometry analysis (Figure 2.9A and 2.9B). Hepatic insulin resistance often 
results in dysregulated hepatic gluconeogenesis that contributes to glucose 
overproduction and obesity-related hyperglycemia [230]. Indeed, we found that the 
livers of CD40-/- mice expressed increased levels of the transcription factor 
forkhead box protein O1 (FOXO1) (Figure 2.10A). The expression of glucose-6-
phosphatase (G6Pase), a key gluconeogenic enzyme, regulated by 
FOXO1/PPARγ coactivator 1α (PGC-1α), was also upregulated in the livers of 
CD40-/- mice (Figure 2.10A).  To test whether gluconeogenesis was increased in 
HFD-fed CD40-/- mice, a pyruvate tolerance test (PTT) was performed with 16-
hour fasted CD40-/- and WT mice. We found that CD40-/- mice displayed 
significantly higher rate of hepatic glucose output by converting pyruvate into 
glucose (Figure 2.10B). These data suggest that hepatic insulin resistance in 
CD40-/- mice leads to elevated levels of hepatic gluconeogenesis. Liver 
inflammation has been proposed as a link between hepatic steatosis and insulin 
resistance [231]. However, in testing liver inflammation in CD40-/- mice, we 
surprisingly found that nucleotide-binding domain and leucine-rich-repeat-
containing protein-3 (NLRP3), interferon-γ (IFNγ), and interleukin-1β (IL-1β) were 
significantly decreased in CD40-/- mice fed HFD (Figure 2.11). In accordance with 
the lower level of inflammatory cytokine secretion in the livers of CD40-/- mice, 
the expression of macrophage marker F4/80 was downregulated (Figure 2.11). 
These data indicate that the hepatic steatosis and insulin resistance observed in 
the CD40-/- mice on HFD occurs independently of liver inflammation.  
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Figure 2.10 CD40-/- mice display elevated hepatic gluconeogenesis  
(A) Expression of genes that encode gluconeogenic transcription factors and 
coactivators (Pgc1α, FOXO1, Hnf4α, Pepck, G6pc) in livers of HFD fed WT and CD40-/- 
mice (n=6).  (B) Pyruvate tolerance test (PTT) for mice (32-week old) on HFD for 24 
weeks (n=8). Animals were fasted overnight, and sodium pyruvate was injected 
intraperitoneally at a dose of 2g/kg of body weight. Data are presented as mean ± S.E.M. 
Statistically signiﬁcant differences between group WT HFD and CD40-/- HFD are 
indicated: *P < 0.05, ** P< 0.01, ***P<0.001. 
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Figure 2.11 CD40-/- mice display decreased hepatic inflammation. 
 Expression of genes (Icam, Vcam, Nlrp3, F4/80, CD68, CD3, IFNγ, TNFα and IL-1β) 
associated with inflammation in livers of WT and CD40-/- mice (n=6). Data are presented 
as mean ± S.E.M. Statistically signiﬁcant differences between group WT HFD and CD40-
/- HFD are indicated: *P < 0.05, ** P< 0.01. 
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2.3.5 CD40-/- mice exhibit increased basal lipolysis in the adipose tissue 
        Lipolysis is a process that releases fatty acids from the adipose tissue 
through hydrolysis of triglyceride stores. Decreased adipose tissue mass and the 
associated lipolysis have been correlated with hepatic steatosis [232]; thus, we 
examined the adipose tissue mass and lipolytic rate of HFD-fed WT and CD40-/- 
mice. There was no statistically significant difference in the percent of lean 
(Figure 2.12A) or fat mass (Figure 2.12B) between CD40-/- mice and WT controls. 
However, when examined histologically (Figure 2.12C), epididymal adipose 
tissue from CD40-/- mice had increased numbers of crown-like structures (CLS). 
CLS are characterized by infiltrating immune cells, especially macrophages, 
surrounding necrotic adipocytes [233] and are a hallmark of adipose tissue 
inflammation, which is associated with increased lipolysis. Indeed, higher basal 
lipolytic activity was observed in the epididymal adipose tissue from CD40-/- mice 
compared with the same adipose tissue from WT mice (Figure 2.13). These data 
suggest that increased adipose tissue lipolysis providing increased fatty acid flux 
to the liver could be a mechanism by which CD40-/- mice develop hepatic 
steatosis. 
 
2.3.6 CD40 depletion increases adipose tissue inflammation 
        Since increased lipolysis and CLS in adipose tissue are often associated 
with increased infiltration of macrophages and other proinflammatory cells, we  
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Figure 2.12 CD40-/- mice have similar lean/fat mass with wild-type mice but 
increased immune cell infiltration in the adipose tissue  
(A) lean mass and (B) fat mass in WT and CD40-/- mice fed HFD was measured by MRI 
analysis as a percentage of total mass over an 11-week period (n=10). (C) 
Representative sections of the epididymal adipose tissue from ND and HFD fed WT and 
CD40-/- mice were stained with hematoxylin-eosin. Arrows indicate crown-like structures. 
(Magnification: 200X)  
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Figure 2.13 CD40-/- mice display elevated adipose tissue lipolysis. 
ex vivo lipolysis assay on epididymal adipose tissue explants from HFD fed WT and 
CD40-/- mice (n=6).  Adipose tissues were incubated in phenol red-free and serum-free 
KRH buffer. Glycerol content in the medium was assayed as an index of lipolysis. 
Epididymal fat pads lipolysis was measured at basal or following stimulation with 10μM 
isoproterenol for 2 hours at 37°C. Data are presented as mean ± S.E.M. Statistically 
signiﬁcant differences between mouse group WT HFD and CD40-/- HFD are indicated: 
*P < 0.05. 
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analyzed epididymal fat pads from the HFD-fed mice for the presence of 
inflammation. 
          First, we measured the presence of cells expressing macrophage surface 
markers F4/80 and CD11b in the SVF of epididymal fat by flow cytometry and did 
not detect a difference (Figure 2.14A). However, the process of isolating SVF 
involves centrifugation to separate adipocytes from the denser SVF cells. 
Therefore, lipid-laden macrophage foam cells, which are F4/80+ CD11b+, can be 
excluded from the SVF because they float to the top and are discarded as part of 
the adipocyte fraction. As such, we measured the expression of macrophage 
markers in whole adipose tissue by real-time qRT-PCR and found that CD11b 
was significantly increased in the HFD fed CD40-/- mice (Figure 2.14B). The 
macrophage population in the epididymal adipose tissue of CD40-/- mice tends to 
have higher expression of the proinflammatory integrin CD11c (Figure 2.14B), 
suggesting an enhanced M1 macrophage polarization in this fat depot [118]. 
Consistently, macrophage infiltration was also increased in the epididymal 
adipose tissue of CD40-/- mice compared with their WT littermate controls (Figure 
2.14C).  
        Since T cells can also infiltrate adipose tissue in HFD-induced obesity and 
contribute to metabolic dysfunction, we measured T cell content in the adipose 
tissue of CD40-/- mice.  We observed a 57% increase of CD3+CD90+ cells in the 
epididymal SVF of HFD fed CD40-/- mice by flow cytometry (Figure 2.15A). This  
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Figure 2.14 CD40 deficiency increases macrophage infiltration in visceral 
adipose tissue 
(A) After 24 weeks on HFD, the SVF was isolated from epididymal adipose tissues of 
WT and CD40-/- mice and analyzed for CD11b and F4/80 expression by flow cytometry. 
Representative dot plots are shown on the left and summarized in bar graph on the right 
(n=8). (B) Gene expression of macrophage markers (F4/80, CD68, CD11b, CD11c and 
MGL-1) from whole epididymal adipose tissues (n=6). (C) Quantitative FACS analysis on 
macrophage population in epididymal adipose tissue of CD40-/- and WT littermate mice 
(18-week old) (n=4). Data are presented as mean ± SEM. Statistically significant 
differences are indicated: *P < 0.05 vs. control. 
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Figure 2.15 CD40 deficiency increases T cell infiltration and inflammation in 
visceral adipose tissue 
(A) After 24 weeks on HFD, the SVF was isolated from epididymal adipose tissues of 
WT and CD40-/- mice and analyzed for CD3 and CD90 expression by flow cytometry. 
Representative dot plots are shown on the left and summarized in bar graph on the right 
(n=8). (B) Gene expression of CD3 from whole epididymal adipose tissues (n=6).  (C) 
Gene expression of inflammatory genes (IFNγ, TNFα, IL-1β, IL-6, CD40, CD154 and 
SAA2) from whole epididymal adipose tissues (n=6). (D) Gene expression of CD31 and 
Von Willebrand factor (vWF) from whole epididymal adipose tissue (n=6). Data are 
presented as mean ± SEM. Statistically significant differences are indicated: P < 0.05, 
**P<0.01 vs control. 
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increase was confirmed by measuring CD3 expression levels by qRT-PCR 
(Figure 2.15B). We also analyzed the mRNA expression of inflammatory 
cytokines to confirm the elevated inflammation in the epididymal fat depot of 
CD40-/- mice. TNFα and IFNγ, two inflammatory cytokines expressed by 
activated macrophages and T cells, were both significantly increased (Figure 
2.15C). As increased obesity and inflammation are often associated with 
increased angiogenesis, we measured endothelial markers CD31 and von 
Willebrand factor (vWF) expression, which were both increased in the CD40-/- 
mice (Figure 2.15D). These results suggest that CD40-/- mice have increased 
adipose tissue inflammation characterized by increased macrophage and T cell 
content and inflammatory cytokine expression. 
 
2.3.7 CD40-/- mice have increased cytotoxic T cell content in the adipose 
tissue 
         Many different subpopulations constitute the normal repertoire of T cells in 
the adipose tissue of obese mice and humans. Nishimura and colleague’s study 
suggested that T cells contribute to the recruitment of ATMs and increased CD8+ 
effector T cells precede the accumulation of macrophages [124]. Therefore, we 
investigated the proportion of these different T cells populations in the epididymal 
adipose tissue of CD40-/- and WT mice by flow cytometry. Of all CD3+CD90+ T 
cells, the percentage of CD4+ cells (TH cells) was decreased by 29% and the  
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Figure 2.16 Deficiency of CD40 leads to increased CD8:CD4 ratio in visceral 
adipose tissue in obese mice 
(A) After 24 weeks on HFD, SVF was isolated from epididymal adipose tissue of WT and CD40-/- 
mice and CD3+CD90+ cells were analyzed for CD4 and CD8a expression by flow cytometry. 
Representative dot plots are shown on the left and summarized in bar graph on the right (n=8). (B) 
Gene expression of CD4 and CD8 in the whole epididymal adipose tissue was measured by qRT-
PCR (n=6). (C) Quantitative FACS analysis on CD8+ T cell population in epididymal adipose 
tissue of CD40-/- and WT littermate mice (18-week old) (n=4) (D) Schematic pie chart showing 
the composition of total T cells defined as CD3+CD90+. Within this subset, Tregs are defined as 
FoxP3+CD4+CD25+. Data are presented as mean ± S.E.M. Statistical significances are indicated: 
*P < 0.05. **P<0.01. ***P<0.001 vs control. 
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Figure 2.17 Deficiency of CD40 leads to increased Tregs in visceral adipose 
tissue in obese mice 
(A) SVF was isolated from epididymal adipose tissue of WT and CD40-/- mice and 
CD3+CD90+CD4+ cells were analyzed for the presence of FoxP3 and CD25 by flow 
cytometry. Representative dot plots are shown on the left and summarized in bar graph 
on the right (n=8). (B) Quantitative FACS analysis on CD4+CD25+FoxP3+  T cell 
population in epididymal adipose tissue of CD40-/- and WT littermate mice (18-week old) 
(n=4) Data are presented as mean ± S.E.M. Statistical significances are indicated: *P < 
0.05. **P<0.01. vs control. 
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Figure 2.18 CD40 deficiency leads to increased eosinophil, B cell and NK/NKT cell 
recruitment into visceral adipose tissue in obese mice. 
After 24 weeks on HFD, SVF was isolated from epididymal adipose tissue of WT and CD40-/- 
mice and analyzed for expression of CD11b, siglec-f (A), Gr-1, CD19 (B), CD3, and NK1.1 (C). 
Representative dot plots are shown on the left and summarized in bar graph on the right (n=8). 
Eosinophils were defined as CD11b+Siglec-f+. B cells were defined as Gr-1-CD19+. NK cells were 
defined as CD3-NK1.1+.  NKT cells were defined as CD3+NK1.1+. (D) Quantitative FACS analysis 
on NK cell population in epididymal adipose tissue of CD40-/- and WT littermate mice (18-week 
old) (n=4) Data are presented as mean ± S.E.M. Statistical significances are indicated: *P < 0.05. 
***P<0.001 vs control. 
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percentage of CD8+ cells (cytotoxic T cell) in adipose tissue was about doubled 
in the CD40-/- mice  (Figure 2.16A, 2.16B and 2.16D). This increase in CD8+ cells 
was also observed when we used WT littermates as the control group (Figure 
2.16C). The percentage of CD25+FoxP3+ Tregs, a subgroup of CD4+ T cells,was 
increased by 82% in the CD40-/- mice (Figure 2.17A), an increase that was also 
observed when WT littermates were used as the control group (Figure 2.17B). In 
summary, the absence of CD40 increased overall T cell abundance in adipose 
tissue and skewed the T cell population of adipose tissue toward increased CD8+ 
cells and decreased CD4+ cells (Figure 2.16D). 
 
2.3.8 CD40-/- mice have increased eosinophil, B cell, NK/NKT cell infiltration 
in adipose tissue 
          The roles of macrophages and T cells in adipose tissue inflammation are 
well described and recently more literatures has shown that other immune cell 
types are also present in obese adipose tissue [140, 142, 146]. As such, we analyzed 
epididymal adipose tissue for the presence of eosinophils (Figure 2.18A), B cells 
(Figure 2.18B), NK and NKT cells (Figure 2.18C) and found that all were 
increased in CD40-/- mice fed HFD. NK cells were also increased in the 
epididymal adipose tissue of CD40-/- mice when WT littermates were used as the 
control group (Figure 2.18D).  
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Discussion 
      The tightly controlled interplay between metabolism and inflammation is 
crucial for the development and maintenance of systemic insulin sensitivity [71]. 
The CD40-CD40L dyad is at the interface of innate and adaptive immunity and 
plays a key role in mediating communication between different cell types in the 
obese adipose tissues [216]. 
            Contrary to the generally accepted concept that disrupting the CD40-
CD40L signaling cascade alleviates inflammation [215, 219], we show here that 
CD40 deficiency in mice unexpectedly aggravates adipose tissue inflammation in 
obesity. This enhanced adipose inflammation in CD40-null mice includes 
increased recruitment of macrophages, CD8+ effector T cells, and other immune 
cells, including B cells, eosinophils, NK cells, NKT cells, and Tregs (Figure 2.14, 
Figure 2.15, Figure 2.16, Figure 2.17 and Figure 2.18). Elevated immune cell 
infiltration into this tissue in CD40-/- mice creates a highly inflamed adipose depot 
characterized by increased levels of inflammatory cytokines (Figure 2.15C) and 
significantly higher basal lipolysis (Figure 2.13). The hydrolyzed FFAs from 
visceral adipose tissue are known to flow into the circulation via the portal vein 
and are then taken up by hepatocytes. This likely contributes to the development 
of the remarkable hepatic steatosis we observed in CD40-/- mice fed HFD (Figure 
2.7D), in the face of the decreased liver inflammation, expected when CD40 is 
deficient (Figure 2.11). With combined adipose tissue inflammation and steatotic 
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liver, CD40-/- mice exhibit dramatic glucose intolerance and systemic insulin 
resistance (Figure 2.3A and Figure 2.6).  
           We found that genetic deficiency of CD40 reduced food intake, which 
attenuated weight gain (Figure 2.1B and Figure 2.1A), observations that were 
also noted in CD40L deficient animals [220]. These findings imply a common role 
of the CD40-CD40L axis in the regulation of energy homeostasis. Reduced food 
intake and body weight gain often correlate with better insulin sensitivity. 
Surprisingly, we found aggravated insulin resistance in these CD40-/- mice as 
assessed by GTT, ITT and hyperinsulinemic-euglycemic clamp measurements 
(Figure 2.6 and Figure 2.3A). Of note, age-matched C57BL/6J mice were used 
as wild-type controls for part of this study. These mice are known to be 
susceptible to diet-induced obesity and display glucose intolerance when fed 
HFD. The genetic locus underlying this phenotype was mapped to nicotinamide 
nucleotide transhydrogenase (Nnt) [234, 235]. C57BL/6J mice have a naturally 
occurring in-frame five-exon deletion in Nnt that removes exons 7-11. Transgenic 
expression of the entire Nnt gene in C57BL/6J mice rescues their glucose 
intolerant phenotype [234]. Importantly, the CD40-/- mice used in this study, which 
are on the C57BL/6Ncr background, having intact Nnt gene, are more insulin 
resistant than the C57BL/6J controls, an effect that is in the opposite direction of 
that expected from the genetic background effect, if any exists, suggesting that 
CD40 plays a critical role in regulating mouse whole body glucose homeostasis. 
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          The decreased steady-state GIR in clamp studies on CD40-/- mice could be 
caused by reduced efficiency of glucose disposal in tissues (muscle, adipose 
tissue, liver, heart and brain) as well as elevated hepatic glucose production. 
Indeed, reduced glucose uptake by brown adipose tissue (BAT) is at least partly 
responsible for the overall decreased GIR in CD40-/- mice (Figure 2.3B). BAT is a 
highly energetic organ that contains large amounts of mitochondria to dissipate 
chemical energy, such as glucose and fatty acids [236]. Our clamp data suggested 
a potential link between receptor CD40 and the activity of BAT. However, more 
future work is needed to elucidate the molecular mechanism involved. 
           Hepatic insulin resistance (Figure 2.9) in CD40-/- mice accounts for part of 
their overall systemic insulin resistance phenotype. We observed increased gene 
expression of major regulators and enzymes (Figure 2.10A) in the 
gluconeogenesis pathway and increased hepatic glucose production in CD40-/- 
mice was confirmed by a pyruvate tolerance test (Figure 2.10B). We were 
unsuccessful in detecting elevated hepatic glucose production in CD40-/- mice 
during our glucose clamp study, but our study compared two groups of mice that 
had been on a high fat diet for 16 weeks, therefore, even the control mice were 
already highly insulin resistant. Thus, suppression of hepatic glucose output by 
insulin was already inhibited in the control mice, making it technically difficult to 
detect a further significant inhibition for CD40-/- mice in the clamp study. 
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          The infiltration of activated macrophages into obese adipose tissue is 
correlated with adipose tissue dysfunction and systemic insulin resistance. CD8+ 
T cells also infiltrate into obese adipose tissue and their depletion improves 
systemic insulin sensitivity, whereas adoptive transfer to CD8-null mice 
aggravates adipose tissue inflammation [124].  Despite reduced body weight, 
CD40-deficient animals on HFD exhibited increased adipose tissue inflammation 
and lipolysis (Figure 2.15C & Figure 2.13). In the present study, we observed 
increased macrophages and T cells in the adipose tissue of CD40-/- mice with T 
cells increasingly biased toward CD8+ cells (Figure 2.14, Figure 2.15, and Figure 
2.16). Importantly, it was reported that CD40 deficiency did not affect 
hematopoietic development or differentiation; therefore, no systemic abnormality 
in the number and ratio of T and B cells was detected in these CD40-null mice 
[195].  Hence, the altered population of immune cells in the adipose tissue of 
CD40-/- mice observed here is likely due to changes in the process of immune cell 
infiltration rather than defects in the development of lymphocytes. In addition to 
elevated macrophage and T cell infiltration into adipose tissue, we also noted a 
general increase of other immune cells, including B cells, eosinophils, NK cells 
and NKT cells (Figure 2.18).  Interestingly, Tregs and eosinophils are typical anti-
inflammatory immune cells and commonly correlated with decreased 
inflammation in obesity [126, 146]. We believe their presence in the inflamed CD40-/- 
adipose tissue may play an important compensatory role to neutralize the 
deleterious effect from the activated macrophage and CD8+ effector T cells. 
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Previous studies on CD40L-/- mice indicated that CD40L deficiency attenuated 
HFD-induced adipose tissue inflammation [220, 222], which is opposite to what we 
observed here in CD40-/- mice.  However, since CD40L can signal through a non-
CD40 pathway [223], differences between CD40-/- and CD40L-/- mouse models are 
not surprising.   
          The surprising elevation in the adipose tissue inflammation (Figure 2.15C) 
in CD40-/- mice was accompanied by an expected decrease in hepatic 
inflammation due to the CD40 deficiency (Figure 2.11). The remarkably elevated 
hepatic steatosis in CD40-/- mice fed a HFD is consistent with two reports on 
CD40L-/- mice [221, 222] but inconsistent with another [220]. The discrepancy among 
different studies on CD40L deficient mice could be due to different sources of 
HFD used in each study. In concert with the morphological changes we observed, 
the more steatotic livers of CD40-/- mice show significantly higher expression of 
hepatic CIDEA and FSP27, two lipid droplet proteins that are not normally 
expressed in lean livers (Figure 2.7F).   
         Studies in rodents and humans have revealed that the accumulation of 
triglycerides observed in hepatic steatosis is mainly due to the increased 
availability of FFAs arising from the visceral adipose tissue through unabated 
lipolysis as well as increased hepatic lipogenesis. These two pathways appear to 
account for more than 80% of the fat storage in steatotic livers [62]. In our study, 
the increased hepatic steatosis in CD40-/- mice may be, in part, a result of fatty 
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acid overﬂow from adipose tissue lipolysis (Figure 2.13).  In addition to the FFAs 
overflow, enhanced de novo lipogenesis also contributes to the formation of 
steatotic liver in CD40-/- mice (Figure 2.8). Chronic exposure of tissues to 
elevated FFAs is known to induce impaired responsiveness of Akt to insulin and 
decreased insulin signaling [237]. Indeed, we observed impaired insulin-mediated 
phosphorylation of Akt (Ser473) in the livers of CD40-/- mice upon acute insulin 
treatment (Figure 2.9). 
         How can the deficiency of a proinflammatory receptor protein that normally 
activates adaptive immunity paradoxically cause elevated inflammation in the 
adipose tissue of mice? We found increased immune cell infiltration in the 
adipose tissue of CD40-/- mice but decreased inflammation in the liver, 
suggesting that the phenotype observed is tissue specific and not due to a global 
defect of the immune system. One possible mechanism could involve endothelial 
cells in adipose tissue. Endothelial cells control leukocyte entry into tissues from 
the vasculature system through the expression of adhesion molecules involved in 
leukocyte rolling and extravasation.  
         Recently, Evans and colleagues’ study shed light on the relationship 
between vasculature network and the regulation of metabolism. They reported 
the role of fibroblast growth factor 1 (FGF1) on adaptive adipose remodeling and 
metabolic homeostasis [238]. Interestingly, FGF1-/- mice exhibit many metabolic 
phenotypes that are very similar to the phenotypes of CD40-/- mice. They showed 
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that FGF1-/- mice displayed no metabolic or histological abnormalities when mice 
were fed a normal chow diet, and when placed on a HFD, FGF1-/- and wild-type 
cohorts showed equivalent changes in serum adipokines, cytokines (leptin, 
resistin, interleukin-6 (IL-6), TNFa, total and high-molecular-weight adiponectin) 
and serum lipids (cholesterol, free fatty acids and triglycerides). These are 
exactly what we observed in the CD40-/- mice compared with age-matched wild-
type cohorts. However, FGF1 is highly induced in adipose tissue in response to 
HFD and that mice lacking FGF1 develop an exaggerated diabetic phenotype 
which is characterized by severe insulin resistance, enlarged steatotic livers, 
dramatically increased ATM infiltration and accentuated inflammatory response. 
Again, these phenotypes are strikingly similar to what we have seen in the HFD-
fed CD40-/- mice. Evans and colleagues suggest that FGF1 mediates the proper 
coupling of nutrient storage to adaptive remodeling of adipose tissue and the 
defects in adipose tissue vasculature are likely responsible for the systemic 
metabolic dysfunction in HFD-fed FGF1-/- mice. 
         CD40 is present on both epithelial and endothelial cells. Different vascular 
beds express various levels of CD40 [239]. Previous studies demonstrated that 
sCD40L reduced the viability and proliferative capacity of endothelial progenitors 
[240] and ligation of CD40 with CD40L prevented endothelial cell migration during 
angiogenesis [241]. In our studies presented here, increased expression of 
endothelial cell markers von Willebrand factor and CD31 in the adipose tissue of 
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CD40-/- mice (Figure 2.15D) suggests an increased presence of endothelial cells. 
In contrast, CD40 expression in the vascular beds of the liver is undetectable [239].  
         During the progression of obesity, the accumulation of proinflammatory 
immune cells in adipose tissue, such as M1 macrophages, TH1, and CD8+ 
effector T cells, normally accompanies with a gradual diminishment of anti-
inflammatory immune cells, such as Tregs and eosinophils. However, in the 
present study, we observed a general increase of a full spectrum of immune cells 
that infiltrate into the visceral fat of CD40-/- mice (Figure 2.18), suggesting that, in 
the absence of CD40, a loss of precise control over the interaction between the 
vascular system and immune cells. It is highly possible that CD40 plays an 
important role in regulating endothelial cell function in the vasculature of adipose 
tissue.  
         To test whether CD40 deficiency affects the permeability of the vascular 
system in the obese visceral fat, thereby alters immune cell infiltration, we 
performed a vascular permeability assay in vivo by injecting Evans Blue Dye via 
tail vein of CD40-/- mice and wild-type controls. Indeed, we found a trend toward 
higher permeability of adipose vasculature in CD40-/- mice on both ND and HFD 
(Figure 3.1). These data suggest a potential leakiness of vasculature in CD40-/- 
adipose tissue and provide a possible explanation for why CD40 deficiency leads 
to higher immune cell infiltration in the adipose tissue. This information also  
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Figure 3.1 Vascular permeability in adipose tissue of  
CD40-/- and wild-type mice 
Evans blue dye (25 mg/kg) was injected into the tail vein of ND or HFD fed CD40-/- and 
wild-type mice (n=6). After one hour, the mice were euthanized by CO2 inhalation and 
were perfused with 30 ml warm PBS via the left ventricle to remove the Evans blue dye 
from the vasculature. The Evans blue dye was extracted from the fat tissue with 1 ml of 
formamide overnight at 55°C and measured at 620 nm. The optical density (OD) value 
was transformed into the concentration according to a standard curve of Evans blue dye. 
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provides us clues critical to understanding how adipose tissue inflammation is 
initiated and propagated in diet-induced obesity.  
         One limitation of our study is that the CD40 deficient mice used here are 
whole body CD40 knockout mice. Further studies are needed to elucidate 
whether tissue-specific knockout of CD40 in endothelial cells might lead to the 
same phenotypes we observed in the current study. How does CD40 affect the 
permeability of adipose vasculature network is another important question for 
future investigations. 
           In summary, results from the present study indicate that CD40 deficiency 
exacerbates inflammation in visceral adipose tissue, further promoting the 
negative metabolic manifestations in obesity, such as insulin resistance and 
hepatic steatosis. This hepatic steatosis is not associated with localized 
inflammation. We thus have identified a unique mouse model whereby an 
apparent primary inflammation and disruption of adipose function leads to 
hepatic steatosis without liver inflammation. These findings reveal the co-
stimulatory signaling CD40-CD40L dyad as an important feature controlling 
adipose tissue inflammation and its connection to metabolic diseases and 
glucose intolerance. 
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Final thoughts 
Gut microbiota and CD40-/- mice metabolism 
          In the past few years, the functional relationship between gut microbiota 
and host metabolism is increasingly recognized owing to technology advances, 
such as next-generation sequencing, high-throughput transcriptomics / 
metabolomics approaches,  and the use of germ-free animals [242, 243]. 
         Gut microbiota refers to the trillions of microorganisms residing in our 
intestine, whose cell count vastly outnumbers our own [244]. These microbial 
inhabitants of the gut have recently been proposed as an environmental factor 
responsible for the altered energy metabolism that accompanies obesity. For 
example, genetically obese ob/ob mice or humans who are obese have more 
Firmicutes and fewer Bacteroidetes in their gut compared with lean healthy 
subjects [245, 246]. Gut microbiota affects host metabolism by ways including, (1) 
the innate immune response to the structural components of bacteria (e.g., LPS) 
resulting in inflammation; and (2) bacterial metabolites of dietary compounds 
(e.g., short-chain fatty acid, SCFA), which have biological activities. 
          It is apparent that the intestinal immune system faces unique challenges, 
as it has to continuously deal with enormous amount of microbial load. As such, 
one essential function of the intestinal immune system is to control the exposure 
of bacteria to host tissues. Various mechanisms are adapted by the host to 
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achieve this goal. For example, intestinal goblet cells create layers of mucus 
coating on the intestinal epithelial cell surface, which serves as a physical barrier 
to block direct contact [247].  Intestinal epithelium also secretes antibacterial 
proteins, such as RegIIIγ and α-defensin, which limit bacterial penetration [248, 249]. 
         Several studies have found the essential role of secreted immunoglobulin A 
(IgA) in preventing intestinal bacteria from breaking the epithelial barrier [250, 251]. 
IgA specific for intestinal bacteria is produced with the help of intestinal dendritic 
cells. These bacteria-laden dendritic cells interact with B and T cells in the 
Peyer’s patches, inducing B cells to produce IgA against intestinal bacteria. Mice 
engineered to lack IgA show priming of serum IgG responses against 
commensals, indicating that these bacteria have been exposed to the systemic 
immune system [250]. 
        Importantly, CD40-/- mice display typical Hyper IgM syndrome, which is 
characterized by normal or elevated concentrations of serum IgM but profound 
reduction of serum IgG, IgE and IgA [195]. Whether this reduced level of IgA in 
CD40-/- mice affects certain gut bacteria growth is not known. 
        The host immune system can control the composition of gut microbiota. 
Studies have shown that mice with immune deficiencies have altered microbial 
communities in the gut. For example, Tbx21-/-/Rag2-/- mice lacking adaptive 
immunity developed ulcerative colitis in a microbiota-dependent manner [252]. 
Similarly, mice deficient in TLR2 exhibited an increase in LPS absorption, 
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subclinical inflammation, insulin resistance, glucose intolerance, and later, 
obesity [253]. 
          Due to limitations of time and the availability of animals, in this study we 
did not perform a metagenomic screen on the gut microbiota of CD40-/- mice and 
the littermate controls, but the potential differences in gut microbiota, if any exist, 
can certainly play a part for the altered metabolic phenotypes in the CD40-/- mice, 
in addition to what we have reported. 
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